HIV Surveillance Summary

Georgia, 2020

HIV/AIDS Epidemiology Section Epidemiology Program Division of Health Protection Georgia Department of Public Health The **HIV Surveillance Summary, Georgia 2020** is published by the Georgia Department of Public Health (DPH), HIV/AIDS Epidemiology Section (HAES), 2 Peachtree Street NW, Atlanta, Georgia 30303. Data are presented from known diagnoses and laboratory reports entered into the Georgia Enhanced HIV/AIDS Reporting System (eHARS). All data are provisional.

The *HIV Surveillance Summary, Georgia 2020* is not copyrighted and may be used and reproduced without permission. Citation of the source is, however, appreciated.

SUGGESTED CITATION: Georgia Department of Public Health, HIV/AIDS Epidemiology Section HIV Surveillance Summary, Georgia 2020, <u>https://dph.georgia.gov/data-fact-sheet-summaries</u>, Published July 2022, [Accessed: date]

ACKNOWLEDGEMENTS: Publication of this report was made possible with the contributions of the Georgia DPH HAES Core HIV Surveillance staff, HIV Case Report Forms submitted by Georgia healthcare facility staff, HIV infection –related laboratory test results transmitted by laboratory facilities in Georgia, data matches with other DPH programs, and the ongoing efforts of multiple individuals from public and private sector organizations dedicated to improving surveillance, prevention, testing, and care of persons living with HIV infection.

Georgia HIV Core Surveillance Team contributors: Jose Adame, Lauren Barrineau-Vejjajiva, Thelma Fannin, Latosha Johnson, Rodriques Lambert, Daniel Mauck, Mildred McGainey, Contessa Meadows, Latoya Moss, Kim Norris, Rama Namballa, Doris Pearson, A. Eugene Pennisi, Sylve Rawls, Akilah Spratling, and Gerriana Willams.

This report was prepared by the following staff from the Georgia Department of Public Health: Nellie Garlow, MPH, Pascale Wortley, MD, MPH; Cherie Drenzek, DVM, MS.

ERRATUM: Table 15. HIV Diagnoses and Persons Living with HIV, District 3-4 (East Metro), Georgia, 2020 has been corrected in this version of the report. The table previously published erroneously showed previous year data.

Table of Contents

INTRODUCTION	5
TECHNICAL NOTES	6
Definitions	6
References	8
TABLES	10
HIV Diagnoses and persons living with HIV, Georgia, 2020	11
Table 1. HIV diagnoses, late diagnoses, and stage 3 (AIDS) diagnoses, Georgia, 2020	11
Table 2. HIV diagnoses, late diagnoses, and stage 3 (AIDS) diagnoses among males, Georgia, 2020	12
Table 3. HIV diagnoses, late diagnoses, and stage 3 (AIDS) diagnoses among females, Georgia, 2020	13
Table 4. HIV diagnoses, late diagnoses, and stage 3 (AIDS) diagnoses among transgender persons, Georgia, 2020)14
Table 5. Persons Living with HIV (PLWH), and PLWH ever Stage 3 (AIDS), Georgia, as of 12/31/2020	15
Table 6. Persons living with HIV (PLWH), and PLWH ever stage 3 (AIDS), males, Georgia, as of 12/31/2020	16
Table 7. Persons Living with HIV (PLWH), and PLWH ever Stage 3 (AIDS), females, Georgia, as of 12/31/2020	17
Table 8. Persons Living with HIV (PLWH), and PLWH ever Stage 3 (AIDS), transgender persons, Georgia, as of 12/31/2020	18
HIV Diagnoses and Persons Living with HIV by Public Health District	19
Table 9. HIV Diagnoses and Persons Living with HIV, District 1-1 (Rome), Georgia, 2020	19
Table 10. HIV Diagnoses and Persons Living with HIV, District 1-2 (Dalton), Georgia, 2020	20
Table 11. HIV Diagnoses and Persons Living with HIV, District 2 (Gainesville), Georgia, 2020	21
Table 12 HIV Diagnoses and Persons Living with HIV, District 3-1 (Cobb-Douglas), Georgia, 2020	22
Table 13. HIV Diagnoses and Persons Living with HIV, District 3-2 (Fulton), Georgia, 2020	23
Table 14. HIV Diagnoses and Persons Living with HIV, District 3-3 (Clayton), Georgia, 2020	24
Table 15. HIV Diagnoses and Persons Living with HIV, District 3-4 (East Metro), Georgia, 2020	25
Table 16. HIV Diagnoses and Persons Living with HIV, District 3-5 (DeKalb), Georgia, 2020	.266
Table 17. HIV Diagnoses and Persons Living with HIV, District 4 (LaGrange), Georgia, 2020	27
Table 18. HIV Diagnoses and Persons Living with HIV, District 5-1 (Dublin), Georgia, 2020	28
Table 19. HIV Diagnoses and Persons Living with HIV, District 5-2 (Macon), Georgia, 2020	29
Table 20. HIV Diagnoses and Persons Living with HIV, District 6 (Augusta), Georgia, 2020	30
Table 21. HIV Diagnoses and Persons Living with HIV, District 7 Columbus), Georgia, 2020	31
Table 22. HIV Diagnoses and Persons Living with HIV, District 8-1 (Valdosta), Georgia, 2020	32
Table 23. HIV Diagnoses and Persons Living with HIV, District 8-2 (Albany), Georgia, 2020	33
Table 24. HIV Diagnoses and Persons Living with HIV, District 9-1 (Savannah), Georgia, 2020	34
Table 25. HIV Diagnoses and Persons Living with HIV, District 9-2 (Waycross), Georgia, 2020	35

Table 26. HIV Diagnoses and Persons Living with HIV, District 10 (Athens), Georgia, 2020
HIV Diagnoses and Persons Living with HIV, Atlanta MSA37
Table 27. HIV Diagnoses and Persons Living with HIV, Atlanta Metropolitan Statistical Area ¹ , Georgia, 2020
Late Diagnoses by Public Health District and Atlanta MSA38
Table 28. Late diagnoses by Public Health District and for Atlanta Metropolitan Statistical Area, Georgia, 202038
Public Health District and County Rates
Table 29. HIV diagnoses and persons living with HIV (PLWH): Public Health District and County number and rates
per 100,000 population, Georgia 2020
Distribution of General Population by Race/Ethnicity43
Table 30. Distribution of the general population by race/ethnicity, Georgia 2020
HIV/AIDS RESOURCES:

INTRODUCTION

HIV infection remains an important public health problem in the state of Georgia. As of the end of 2020, there were 60,073 persons living with HIV in Georgia, and 2,018 persons were diagnosed in 2020. The number of persons living with HIV continues to increase, because of effective therapies now available. Based on the Centers for Disease Control and Prevention's 2019 HIV Surveillance Report, Georgia was ranked the fourth highest in the nation for both the total number of new diagnoses of HIV infection among adults and adolescents after Florida, California, and Texas, and ranked the fifth highest for the number of persons living with HIV infection, after Florida, California, Texas, and New York¹. Georgia ranked 2nd in the rate of HIV diagnosis among adults and adolescents, and 4th in the rate of persons living with HIV.

Monitoring the HIV/AIDS epidemic and understanding the burden of HIV infection in Georgia are essential for meeting the goals stated in the 2022-2025 National HIV/AIDS Strategy to: 1) prevent new HIV infections; 2) improve HIV-related health outcomes for persons living with HIV; 3) reduce HIV-related health disparities and inequities, and 4) achieve a more coordinated national response to the HIV epidemic among all partners and stakeholders.² Information on the Georgia HIV care continuum can be found in a separate report at the following web page: <u>https://dph.georgia.gov/hiv-care-continuum.</u>

Interpreting HIV Surveillance Data During the COVID-19 Pandemic

After the COVID-19 pandemic was declared a national and state emergency in March 2020, access to healthcare services, including HIV testing, prevention, and care-related services, became reduced or temporarily suspended. Therefore, decreases seen in 2020 HIV diagnoses may partly represent decreased availability of HIV testing or delays in seeking HIV testing. As a result, 2020 HIV surveillance data should be interpreted with caution.

TECHNICAL NOTES

Georgia statutes and regulations (O.C.G.A. §31-12-2(b)) require healthcare providers (such as nurses, nurse practitioners, doctors, physician assistants) licensed in the state of Georgia to report all cases of HIV infection and/or Stage 3 (AIDS) to the Georgia DPH within seven days of diagnosis³. Laboratories licensed in the state of Georgia are required to report all HIV-related laboratory test results within 7 days. The information is used to monitor the HIV/AIDS epidemic in Georgia and guide program planning and evaluation. The data presented in the accompanying tables are based on confidential case reports collected through the Georgia DPH enhanced HIV/AIDS Reporting System (eHARS).

AIDS reporting began in the early 1980s, and HIV reporting began in Georgia on December 31, 2003. Electronic transmission of laboratory test results began in 2011. Receipt of CD4 counts and viral load tests make it possible to estimate the HIV Care Continuum for persons with a diagnosis of HIV infection in the state of Georgia (reports are available at: <u>https://dph.georgia.gov/hiv-care-</u> <u>continuum</u>).

This report includes surveillance data reported through December 31, 2021 for cases diagnosed through December 31, 2020. This report is limited to cases diagnosed through December 2020 to take into account delays in reporting, and to allow for obtaining follow up information on reported cases. HIV diagnoses include persons with a diagnosis of HIV infection, regardless of the stage of disease at diagnosis, who were residents of Georgia at the time of diagnosis. Persons living with HIV are those with a residence in the state of Georgia, based on current information available in the Georgia HIV/AIDS surveillance system, regardless of where they resided at the time of diagnosis. Persons residing in correctional facilities are included in this report and may inflate rates in certain geographic regions where there are large numbers of HIV-positive inmates.

Information on transmission category is missing for one quarter of cases. Multiple imputation, a statistical approach, is used to replace each missing transmission category with a set of plausible values that represent the uncertainty about the true, but missing, value⁴. The methods were applied to adult and adolescent, but not pediatric cases. Multiple imputation is considered by the Centers for Disease Control and Prevention to be the best method for redistribution of missing data in large databases. Transmission category is shown with missing data, and after multiple imputation. Cases missing race/ethnicity are not assigned a risk through multiple imputation.

Persons for whom the current identity box "transgender" was checked on the case report form are classified as transgender. Because providers often do not complete all case report form fields, the numbers reported here are most likely an underestimate. Additionally, because the current identity fields were added to the case report form in 2007, prevalent counts of HIV among transgender persons may be incomplete.

Persons with transmission category "perinatal/other pediatric" include infants born in Georgia who acquired HIV through perinatal transmission, as well as infants born outside of Georgia who acquired HIV through perinatal transmission and were first diagnosed with HIV in Georgia. For more information on perinatal HIV exposure surveillance in Georgia, see the Perinatal HIV Exposure Surveillance Report at <u>https://dph.georgia.gov/epidemiology/georgias-hivaids-</u> epidemiology-section/georgia-hiv-surveillance-data.

For data presented at the Public Health District or MSA level, all cells with values between 1 and 4 observations are censored in accordance with the Georgia Department of Public Health HIV Surveillance Security and Confidentiality Guidelines.

Definitions

HIV DIAGNOSES are cases diagnosed between January 1 and December 31, 2020, with an address at the time of HIV diagnosis was in Georgia, and who were reported to the Georgia Department of Public Health by December 31, 2020, regardless of stage at diagnosis. This group includes persons whose initial diagnosis is Stage 3 (AIDS).

LATE DIAGNOSES are the subset of HIV diagnoses who

are found to be Stage 3 (AIDS) within 12 months of HIV diagnosis date. Such persons are termed late diagnoses because their advanced stage at diagnosis indicates that they were most likely infected for many years before diagnosis.

STAGE 3 (AIDS) DIAGNOSES include two groups: 1) persons newly diagnosed with HIV in 2020, found to meet the definition for Stage 3 (AIDS) at diagnosis, and with an address at or near the time of Stage 3 diagnosis in Georgia; and, 2) persons found to meet the Stage 3 definition in 2020 with an address at or near the time of Stage 3 diagnosis in Georgia, regardless of the date of their initial HIV diagnosis.

PERSONS LIVING WITH HIV INFECTION are persons diagnosed by December 31, 2020, who are not known to be deceased, and for whom the most recent address available is in Georgia.

PERSONS LIVING WITH HIV, EVER STAGE 3 are persons diagnosed by December 31, 2020, who are not known to be deceased, for whom the most recent address available is in Georgia, and who met the case definition for Stage 3 (AIDS) at some point.

TRANSMISSION CATEGORIES presented in this report follow the standards created by the Centers for Disease Control and Prevention (CDC) and have been used for many years. According to the CDC, *transmission category* is the term for the classification of cases that summarizes a person's possible HIV risk factors. The summary classification results from selecting the one most likely risk factor to have been responsible for HIV transmission from the presumed hierarchical order of probability. For surveillance purposes, HIV and AIDS cases are counted only once in the hierarchy of transmission categories. Persons with more than one reported risk factor for HIV infection are classified in the transmission category according to the behavior that is most likely to have resulted in transmission. The exception is men who report sexual contact with other men and injection drug use; this group makes up a separate transmission category. Persons whose transmission category is classified as heterosexual contact are persons who report heterosexual contact specifically with a person known to have or be at high risk for HIV infection (e.g., an injection drug user/IDU). The term *high risk* is not included in the transmission category label for heterosexual contact in the tables because heterosexual contact itself is the risk factor most likely to have been responsible for transmission. However, the Table 3 footnote regarding this category clarifies how the data are defined: "heterosexual contact with a person known to have, or to be at high risk for, HIV infection".

CURRENT RESIDENCE Current address is determined using the date of the most recently-entered residential address as of 12/31/2020 into the Georgia eHARS. The number of persons living with HIV is based on current address.

VITAL STATUS: Persons are assumed to be alive unless otherwise documented or reported. The Georgia DPH performs an annual match of the eHARS database with the Georgia Vital Records death data, the National Death Index and the Social Security Death Index to ascertain vital status. **RATES:** Denominators for population rates are based on the 2020 estimates of the Georgia resident population retrieved from the Georgia Department of Public Health, Office of Health Indicators for Planning (OHIP). Rates are per 100,000 population. Rates are not presented for case numbers less than 12 because these rates have relative standard errors greater than 30% and are considered unreliable.

PERCENTAGES: Total percentages may not add up to 100% due to rounding.

COUNTS: Counts in the gender, race/ethnicity, and age categories may not add up to the overall totals due to a small number of cases with missing information (<2 percent).

References

1. Centers for Disease Control and Prevention. *HIV Surveillance Report, 2019*; vol.32. <u>http://www.cdc.gov/hiv/library/reports/hiv-</u> surveillance.html. Published May 2021.

2. White House Office of National AIDS Policy. *National HIV/AIDS Strategy (2022-2025)*. <u>https://hivgov-prod-</u> <u>v3.s3.amazonaws.com/s3fs-public/NHAS-2022-</u> <u>2025.pdf</u>. Published 2021.

Department of Public Health, Rules and regulations
 290-48.11 (2003); Official Code of Georgia Annotated
 (O.C.G.A.) § 31-22-9.2 (2011)

4. Harrison KM, Kajese T, Hall HI, Song R. Risk factor redistribution of the national HIV/AIDS surveillance data: an alternative approach. Public Health Rep 2008;123:618–27.

TABLES

HIV Diagnoses and persons living with HIV, Georgia, 2020

Table 1. HIV diagnoses, late diagnoses, and stage 3 (AIDS) diagnoses, Georgia, 2020

Data for 2020 diagnoses should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing

		agnoses tages)	Late HIV Diagnoses ¹			Stage 3 (AIDS) Diagnoses ²	
	N	%*	N	%*	row %	N	%*
Total	2,016	100	460	100	22.8	1,088	100
Gender Identity							
Cisgender Male	1,548	76.7	342	74.3	22.1	821	75.4
Cisgender Female	409	20.3	103	22.4	25.2	235	21.6
Transgender Persons	59	2.9	15	3.3	25.4	32	2.9
Race/Ethnicity							
Black/Non Hispanic	1,457	72.2	325	70.7	22.3	799	73.4
White/Non Hispanic	321	15.9	73	15.9	22.7	158	14.5
Hispanic/Latino, Any Race	177	8.8	46	10.0	26.0	91	8.4
American Indian/Alaska Native	2	0.1	1	0.2	50.0	1	0.1
Asian/Native Hawaiian/Pacific Islander	17	0.8	9	2.0	52.9	14	1.3
Multiple races	20	1.0	1	0.2	5.0	19	1.7
Age Group at Diagnosis (Years)							
<13	2	0.1	0	0.0	0.0	0	0.0
13-19	100	5.0	9	2.0	9.0	11	1.0
20-29	815	40.4	134	29.1	16.4	257	23.6
30-39	561	27.8	128	27.8	22.8	321	29.5
40-49	257	12.7	93	20.2	36.2	229	21.0
50-59	204	10.1	69	15.0	33.8	179	16.4
60+	79	3.9	27	5.9	34.2	92	8.4
Transmission Category (Unadjusted)							
Male-to-male sexual contact	1,126	55.8	222	48.3	19.7	539	49.5
Injection drug use	35	1.7	4	0.9	11.4	32	2.9
Male-to-male sexual contact and injection drug use	27	1.3	4	0.9	14.8	24	2.2
Heterosexual contact ³	364	18.0	108	23.5	29.7	224	20.6
Perinatal/other pediatric ⁴	0	0.0	0	0.0		1	0.1
Unknown	466	23.1	122	26.5	26.2	268	24.6
Transmission Category (Adjusted) ⁵							
Male-to-male sexual contact	1,356	67.2	280	60.8	20.6	668	61.3
Injection drug use	64	3.2	13	2.8	20.3	50	4.6
Male-to-male sexual contact and injection drug use	35	1.7	6	1.3	17.1	30	2.8
Heterosexual contact ³	539	26.7	156	34.0	28.9	329	30.2
Perinatal/other pediatric ⁴	0	0.0	0	0.0		1	0.1

*Percentages may not add up to 100% due to rounding. 1. Late diagnosis: stage 3 (AIDS) diagnosis within 12 months of HIV diagnosis. Row % is percent of HIV diagnoses that were late diagnoses 2. Stage 3 (AIDS): includes persons diagnosed with stage 3 in 2020, regardless of year of HIV diagnosis. 3. Heterosexual contact: Defined as sexual contact with someone of the opposite sex with known risk such as injection drug use, bisexual male (applies to females only), person with. hemophilia/coagulation disorder, transfusion recipient with HIV documentation, and or person with AIDS or documented HIV. 4. Perinatal/other pediatric: cases <13 born to HIV-infected mother, cases <13 with missing risk, and cases <13 with other risk (e.g. sexual transmission). 5. Adjusted for missing risk using multiple imputation methods. Adjusted subtotals may be different from unadjusted subtotals due to rounding.

Table 2. HIV diagnoses, late diagnoses, and stage 3 (AIDS) diagnoses among Cis-Gender Males, Georgia, 2020

Data for 2020 diagnoses should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing

	HIV Diag (all sta		Late	HIV Diagn	oses1	Stage 3 Diagno	
	Ν	%*	N	%*	row %	N	%*
Total	1,546	100.0	342	100.0	22.1	821	100.0
Race/Ethnicity							
Black/Non Hispanic	1,103	71.3	240	70.2	21.8	595	72.5
White/Non Hispanic	240	15.5	50	14.6	20.8	120	14.6
Hispanic/Latino, Any Race	153	9.9	40	11.7	26.1	74	9.0
American Indian/Alaska Native	2	0.1	1	0.3	50.0	1	0.1
Asian/Native Hawaiian/Pacific Islander	11	0.7	5	1.5	45.5	10	1.2
Multiple races	17	1.1	1	0.3	5.9	15	1.8
Age Group at Diagnosis (Years)							
<13	1	0.1	0	0.0	0.0	0	0.0
13-19	75	4.8	8	2.3	10.7	9	1.1
20-29	675	43.6	112	32.7	16.6	212	25.8
30-39	448	28.9	101	29.5	22.5	260	31.7
40-49	164	10.6	61	17.8	37.2	151	18.4
50-59	139	9.0	48	14.0	34.5	126	15.3
60+	46	3.0	12	3.5	26.1	63	7.7
Transmission Category (Unadjusted)							
Male-to-male sexual contact	1,069	69.1	207	60.5	19.4	508	61.9
Injection drug use	21	1.4	2	0.6	9.5	21	2.6
Male-to-male sexual contact and injection drug use	26	1.7	4	1.2	15.4	23	2.8
Heterosexual contact ³	125	8.1	48	14.0	38.4	90	11.0
Perinatal/other pediatric ⁴	0	0.0	0	0.0		0	0.0
Unknown	307	19.8	81	23.7	26.4	178	21.7
Transmission Category (Adjusted) ⁵							
Male-to-male sexual contact	1,299	83.9	265	77.4	20.4	637	77.6
Injection drug use	33	2.1	6	1.7	18.2	29	3.6
Male-to-male sexual contact and injection drug use	34	2.2	6	1.8	17.6	29	3.6
Heterosexual contact ³	161	10.4	60	17.6	37.3	117	14.2
Perinatal/other pediatric ⁴	0	0.0	0	0.0		0	0.0

* Percentages may not add up to 100% due to rounding. 1. Late diagnosis: stage 3 (AIDS) diagnosis within 12 months of HIV diagnosis. Row % is percent of HIV diagnoses that were late diagnoses 2. Stage 3 (AIDS): includes persons diagnosed with stage 3 in 2020, regardless of year of HIV diagnosis. 3. Heterosexual contact: Defined as sexual contact with someone of the opposite sex with known risk such as injection drug use, bisexual male (applies to females only), person with. hemophilia/coagulation disorder, transfusion recipient with HIV documentation, and or person with AIDS or documented HIV. 4. Perinatal/other pediatric: cases born to HIV-infected mother, cases <13 with missing risk, and cases <13 with other risk (e.g. sexual transmission). 5. Adjusted for missing risk using multiple imputation methods. Adjusted subtotals may be different from unadjusted subtotals due to rounding.

Table 3. HIV diagnoses, late diagnoses, and stage 3 (AIDS) diagnoses among Cis-Gender Females, Georgia, 2020

Data for 2020 diagnoses should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing

			Late HIV Diagnoses ¹			ge 3 (AIDS) iagnoses ²	
	N	%*	N	%*	row %	N	%*
Total	407	100.0	103	100.0	25.3	234	100.0
Race/Ethnicity							
Black/Non Hispanic	308	75.3	75	72.8	24.4	180	76.6
White/Non Hispanic	71	17.4	20	19.4	28.2	34	14.5
Hispanic/Latino, Any Race	19	4.6	4	3.9	21.1	12	5.1
American Indian/Alaska Native	0	0.0	0	0.0		0	0.0
Asian/Native Hawaiian/Pacific Islander	6	1.5	4	3.9	66.7	4	1.7
Multiple races	3	0.7	0	0.0	0.0	4	1.7
Age Group at Diagnosis (Years)							
<13	1	0.2	0	0.0	0.0	0	0.0
13-19	22	5.4	0	0.0	0.0	1	0.4
20-29	104	25.4	15	14.6	14.4	29	12.3
30-39	96	23.5	21	20.4	21.9	51	21.7
40-49	88	21.5	31	30.1	35.2	74	31.5
50-59	65	15.9	21	20.4	32.3	51	21.7
60+	33	8.1	15	14.6	45.5	29	12.3
Transmission Category (Unadjusted)							
Injection drug use	14	3.4	2	1.9	14.3	11	4.7
Heterosexual contact ³	238	58.2	60	58.3	25.2	134	57.0
Perinatal/other pediatric ⁴	0	0.0	0	0.0		1	0.4
Unknown	157	38.4	41	39.8	26.1	89	37.9
Transmission Category (Adjusted) ⁵							
Injection drug use	31	7.5	7	6.6	22.6	21	8.9
Heterosexual contact ³	375	91.8	96	93.4	25.6	212	90.3
Perinatal/other pediatric ⁴	0	0.0	0	0.0		1	0.4

* Percentages may not add up to 100% due to rounding. 1. Late diagnosis: stage 3 (AIDS) diagnosis within 12 months of HIV diagnosis. Row % is percent of HIV diagnoses that were late diagnoses 2. Stage 3 (AIDS): includes persons diagnosed with stage 3 in 2020, regardless of year of HIV diagnosis. 3.
Heterosexual contact: Defined as sexual contact with someone of the opposite sex with known risk such as injection drug use, bisexual male (applies to females only), person with. hemophilia/coagulation disorder, transfusion recipient with HIV documentation, and or person with AIDS or documented HIV.
4. Perinatal/other pediatric: cases born to HIV-infected mother, cases <13 with missing risk, and cases <13 with other risk (e.g. sexual transmission). 5.
Adjusted for missing risk using multiple imputation methods. Adjusted subtotals may be different from unadjusted subtotals due to rounding.

Table 4. HIV diagnoses, late diagnoses, and stage 3 (AIDS) diagnoses among Transgender Persons,

Georgia, 2020

Data for 2020 diagnoses should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing

	HIV Diag (all sta		Late HIV Diagnoses ¹			agnoses ¹ Stage 3 (AIDS) Diagnoses ²	
	N	%*	N	%*	row %	N	%*
Total	59	100.0	15	100.0	25.4	32	100.0
Gender Identity							
Transgender Woman	57	96.6	15	100.0	26.3	32	100.0
Transgender Man	2	3.4	0	0.0	0.0	0	0.0
Race/Ethnicity							
Black/Non Hispanic	45	76.3	10	66.7	22.2	24	75.0
White/Non Hispanic	9	15.3	3	20.0	33.3	4	12.5
Hispanic/Latino, Any Race	5	8.5	2	13.3	40.0	4	12.5
American Indian/Alaska Native	0	0.0	0	0.0		0	0.0
Asian/Native Hawaiian/Pacific Islander	0	0.0	0	0.0		0	0.0
Multiple races	0	0.0	0	0.0		0	0.0
Age Group at Diagnosis (Years)							
13-19	2	3.4	1	6.7	50.0	1	3.1
20-29	35	59.3	7	46.7	20.0	15	46.9
30-39	17	28.8	6	40.0	35.3	10	31.3
40-49	5	8.5	1	6.7	20.0	4	12.5
50-59	0	0.0	0	0.0		2	6.3
60+	0	0.0	0	0.0		0	0.0
Transmission Category (Unadjusted)							
Sexual contact ³	57	96.5	15	100.0	26.3	31	96.9
Sexual contact and injection drug use	1	1.7	0	0.0	0.0	1	3.1
Unknown	1	1.7	0	0.0	0.0	0	0.0
Transmission Category (Adjusted) ⁴							
Sexual contact ³	28	98.3	15	100.0		31	96.9
Sexual contact and injection drug use	1	1.7	0	0.0		1	3.1
Injection drug use	0	0.0	0	0.0	0.0	0	0.0
			0	0.0	0.0	0	0.0

1. Late diagnosis: stage 3 (AIDS) diagnosis within 12 months of HIV diagnosis. 2. Stage 3 (AIDS): includes persons diagnosed with stage 3 in 2020, regardless of year of HIV diagnosis. 3. Includes sex with male and probable heterosexual transmission as noted in medical chart. 4. Adjusted for missing risk using multiple imputation methods. Adjusted subtotals may be different from unadjusted subtotals due to rounding.

Table 5. Persons Living with HIV (PLWH), and PLWH ever Stage 3 (AIDS), Georgia, as of 12/31/2020

60+10,46117.46,74822.4Transmission Category (Unadjusted)Male-to-male sexual contact30,44050.714,69148.7Injection drug use2,2943.81,6085.3Male-to-male sexual contact and injection drug use1,8773.11,2074.0Heterosexual contact ² 10,05816.75,61618.6Adult Other ³ 5690.92891.0Perinatal/other pediatric ⁴ 730.1200.1Unknown14,76224.66,74422.4Transmission Category (Adjusted) ⁵ Male-to-male sexual contact37,04461.717,69658.6Injection drug use3,3605.62,2147.3Male-to-male sexual contact and injection drug use2,3143.91,4514.8Heterosexual contact ² 15,73926.28,33827.6Adult Other ³ 5690.92891.0		PLWł	4	Ever Stage 3 (AIDS) ¹		
Classe Classe <thclas< th=""> Clas</thclas<>		N	%*	N	%*	
Clisgender Male 45,156 7.5.2 22,612 74.9 Cisgender Fernale 14,110 23.5 7,211 23.9 Transgender Persons 683 1.1 311 1.0 Race/Ethnicity 9 68.2 20,908 69.3 White/Non Hispanic 10,462 17.4 5,121 17.0 Hispanic/Latino, Any Race 4.516 7.5 2,266 7.5 American Indian/Alaska Native 28 0.0 11 0.0 Asian/Native Hawaiian/Pacific Islander 320 0.5 118 0.4 Multiple races 2.785 4.6 1,588 5.3 Current Age Group (Years)	Total	59,949	100.0	30,134	100.0	
Cisgender Fernale 14,110 23,5 7,211 23,9 Transgender Persons 683 1.1 311 1.0 Race/Ethnicity	Gender Identity					
Transgender Persons 683 1.1 311 1.0 Race/Ethnicity Black/Non Hispanic 40,999 68.2 20,908 69.3 White/Non Hispanic 10,462 17.4 5,121 17.0 Hispanic/Latino, Any Race 4,516 7.5 2,266 7.5 American Indian/Alaska Native 28 0.0 11 0.0 Asian/Native Hawaiian/Pacific Islander 320 0.5 118 0.4 Multiple races 2,785 4.6 1,588 5.3 Current Age Group (Years) 2 302 0.5 44 0.1 20-29 6,710 11.2 1,556 5.2 30-39 14,088 23.5 5,362 17.8 40-49 12,627 21.0 6,679 22.1 50-59 15,792 26.3 9,762 32.4 Male-to-male sexual contact 30,440 50.7 14,691 48.7 Injection drug use 1,877 3.1 1,207 4.0	Cisgender Male	45,156	75.2	22,612	74.9	
Rac/Ethnicity Black/Non Hispanic 40,999 68.2 20,908 69.3 White/Non Hispanic 10,462 17.4 5,121 17.0 Hispanic/Latino, Any Race 4,516 7.5 2,266 7.5 American Indian/Alaska Native 28 0.0 11 0.0 Asian/Native Hawaiian/Pacific Islander 320 0.5 118 0.4 Multiple races 2,785 4.6 1,588 5.3 Current Age Group (Years) 2 1.1 0.0 302 0.5 44 0.1 20-29 6,710 11.2 1,556 5.2 30.39 14,088 23.5 5.362 17.8 40-49 12,627 21.0 6.679 22.1 50.59 15,792 26.3 9,762 32.4 60+ 10,461 17.4 6,74 48.7 11.6 6.67 22.4 Hale-to-male sexual contact 30,440 50.7 14,691 48.7 11.6 6.7 4.0	Cisgender Female	14,110	23.5	7,211	23.9	
Black/Non Hispanic 40,999 68.2 20,908 69.3 White/Non Hispanic 10,462 17.4 5,121 17.0 Hispanic/Latino, Any Race 4,516 7.5 2,266 7.5 American Indian/Alaska Native 28 0.0 11 0.0 Asian/Native Hawaiian/Pacific Islander 320 0.5 118 0.4 Multiple races 2,785 4.6 1,588 5.3 Current Age Group (Years)	Transgender Persons	683	1.1	311	1.0	
White/Non Hispanic 10,462 17.4 5,121 17.0 Hispanic/Latino, Any Race 4,516 7.5 2,266 7.5 American Indian/Alaska Native 28 0.0 11 0.0 Asian/Native Hawaiian/Pacific Islander 320 0.5 118 0.4 Multiple races 2,785 4.6 1,588 5.3 Current Age Group (Years) 1 22 0.1 13-19 302 0.5 444 0.1 20-29 6,710 11.2 1,556 5.2 30-39 14,088 23.5 5,362 17.8 40-49 12,627 21.0 6,679 22.1 50-59 15,792 26.3 9,762 32.4 60+ 10,461 17.4 6,769 32.4 Male-to-male sexual contact 30,440 50.7 14,691 48.7 Injection drug use 2,294 3.8 1,608 5.3 Adle-to-male sexual contact 10,058 16.7	Race/Ethnicity					
Hispanic/Latino, Any Race 4,516 7.5 2,266 7.5 American Indian/Alaska Native 28 0.0 11 0.0 Asian/Native Hawaiian/Pacific Islander 320 0.5 118 0.4 Multiple races 2,785 4.6 1,588 5.3 Current Age Group (Years) 1 22 0.1 13-19 302 0.5 44 0.1 20-29 6,710 11.2 1,556 5.2 30-39 14,088 23.5 5,362 17.8 40-49 12,627 21.0 6,679 22.1 50-59 15,792 26.3 9,762 32.4 60+ 10,461 17.4 6,748 22.4 Injection drug use 2,294 3.8 1,608 5.3 Male-to-male sexual contact 30,440 50.7 14,691 48.7 Injection drug use 2,294 3.8 1,608 5.3 Adle-to-male sexual contact 10,058 16.7 <td>Black/Non Hispanic</td> <td>40,999</td> <td>68.2</td> <td>20,908</td> <td>69.3</td>	Black/Non Hispanic	40,999	68.2	20,908	69.3	
American Indian/Alaska Native 28 0.0 11 0.0 Asian/Native Hawaiian/Pacific Islander 320 0.5 118 0.4 Multiple races 2,785 4.6 1,588 5.3 Current Age Group (Years)	White/Non Hispanic	10,462	17.4	5,121	17.0	
Asian/Native Hawaiian/Pacific Islander 320 0.5 118 0.4 Multiple races 2,785 4.6 1,588 5.3 Current Age Group (Years) 81 0.1 22 0.1 13-19 302 0.5 444 0.1 20-29 6,710 11.2 1,556 5.2 30-39 14,088 23.5 5,362 17.8 40-49 12,627 21.0 6,679 22.1 50-59 15,792 26.3 9,762 32.4 60+ 10,461 17.4 6,748 22.4 Male-to-male sexual contact 30,440 50.7 14,691 48.7 Injection drug use 2,294 3.8 1,608 5.3 Male-to-male sexual contact 30,440 50.7 14,691 48.7 Injection drug use 1,877 3.1 1,207 4.0 Heterosexual contact ² 10,058 16.7 5,616 18.6 Adult Other ³ 569	Hispanic/Latino, Any Race	4,516	7.5	2,266	7.5	
Multiple races 2,785 4.6 1,588 5.3 Current Age Group (Years) 3 1 2 0.1 <13	American Indian/Alaska Native	28	0.0	11	0.0	
Age Group (Years) <13	Asian/Native Hawaiian/Pacific Islander	320	0.5	118	0.4	
<13	Multiple races	2,785	4.6	1,588	5.3	
13-19 302 0.5 44 0.1 20-29 6,710 11.2 1,556 5.2 30-39 14,088 23.5 5,362 17.8 40-49 12,627 21.0 6,679 22.1 50-59 15,792 26.3 9,762 32.4 60+ 10,461 17.4 6,748 22.4 Transmission Category (Unadjusted) 30,440 50.7 14,691 48.7 Injection drug use 2,294 3.8 1,608 5.3 Male-to-male sexual contact 30,440 50.7 14,691 48.7 Injection drug use 2,294 3.8 1,608 5.3 Male-to-male sexual contact? 10,058 16.7 5,616 18.6 Adult Other ³ 569 0.9 289 1.0 Perinatal/other pediatric ⁴ 73 0.1 20 0.1 Unknown 14,762 24.6 6,744 22.4 Male-to-male sexual contact 37,044 61.7 17,696 58.6 Injection drug use 3,360	Current Age Group (Years)					
20-29 6,710 11.2 1,556 5.2 30-39 14,088 23.5 5,362 17.8 40-49 12,627 21.0 6,679 22.1 50-59 15,792 26.3 9,762 32.4 60+ 10,461 17.4 6,748 22.4 Transmission Category (Unadjusted) 17.4 6,748 22.4 Male-to-male sexual contact 30,440 50.7 14,691 48.7 Injection drug use 2,294 3.8 1,608 5.3 Male-to-male sexual contact and injection drug use 1,877 3.1 1,207 4.0 Heterosexual contact ² 10,058 16.7 5,616 18.6 Adult Other ³ 569 0.9 289 1.0 Perinatal/other pediatric ⁴ 73 0.1 20 0.1 Unknown 14,762 24.6 6,744 22.4 Male-to-male sexual contact 37,044 61.7 17,696 58.6 Injection drug use	<13	81	0.1	22	0.1	
30-39 14,088 23.5 5,362 17.8 40-49 12,627 21.0 6,679 22.1 50-59 15,792 26.3 9,762 32.4 60+ 10,461 17.4 6,748 22.4 Transmission Category (Unadjusted) 17.4 6,748 22.4 Male-to-male sexual contact 30,440 50.7 14,691 48.7 Injection drug use 2,294 3.8 1,608 5.3 Male-to-male sexual contact and injection drug use 1,877 3.1 1,207 4.0 Heterosexual contact ² 10,058 16.7 5,616 18.6 Adult Other ³ 569 0.9 289 1.0 Perinatal/other pediatric ⁴ 73 0.1 20 0.1 Unknown 14,762 24.6 6,744 22.4 Male-to-male sexual contact 37,044 61.7 17,696 58.6 Injection drug use 3,360 5.6 2,214 7.3 Male-to-male sexual contact and injection drug use 2,314 3.9 1,451 4.8 <td>13-19</td> <td>302</td> <td>0.5</td> <td>44</td> <td>0.1</td>	13-19	302	0.5	44	0.1	
40-4912,62721.06,67922.150-5915,79226.39,76232.460+10,46117.46,74822.4Transmission Category (Unadjusted)Male-to-male sexual contact30,44050.714,69148.7Injection drug use2,2943.81,6085.3Male-to-male sexual contact and injection drug use1,8773.11,2074.0Heterosexual contact ² 10,05816.75,61618.6Adult Other ³ 5690.92891.0Perinatal/other pediatric ⁴ 730.1200.1Unknown14,76224.66,74422.4Transmission Category (Adjusted) ⁵ Male-to-male sexual contact37,04461.717,69658.6Injection drug use3,3605.62,2147.3Male-to-male sexual contact and injection drug use2,3143.91,4514.8Heterosexual contact ² 15,73926.28,33827.6Adult Other ³ 5690.92891.0	20-29	6,710	11.2	1,556	5.2	
50-5915,79226.39,76232.460+10,46117.46,74822.4Transmission Category (Unadjusted)Male-to-male sexual contact30,44050.714,69148.7Injection drug use2,2943.81,6085.3Male-to-male sexual contact and injection drug use1,8773.11,2074.0Heterosexual contact ² 10,05816.75,61618.6Adult Other ³ 5690.92891.0Perinatal/other pediatric ⁴ 730.1200.1Unknown14,76224.66,74422.4Transmission Category (Adjusted) ⁵ Male-to-male sexual contact37,04461.717,69658.6Injection drug use3,3605.62,2147.3Male-to-male sexual contact and injection drug use2,3143.91,4514.8Heterosexual contact ² 15,73926.28,33827.6Adult Other ³ 5690.92891.0	30-39	14,088	23.5	5,362	17.8	
60+10,46117.46,74822.4Transmission Category (Unadjusted)Male-to-male sexual contact30,44050.714,69148.7Injection drug use2,2943.81,6085.3Male-to-male sexual contact and injection drug use1,8773.11,2074.0Heterosexual contact ² 10,05816.75,61618.6Adult Other ³ 5690.92891.0Perinatal/other pediatric ⁴ 730.1200.1Unknown14,76224.66,74422.4Transmission Category (Adjusted) ⁵ Male-to-male sexual contact37,04461.717,69658.6Injection drug use3,3605.62,2147.3Male-to-male sexual contact and injection drug use2,3143.91,4514.8Heterosexual contact ² 15,73926.28,33827.6Adult Other ³ 5690.92891.0	40-49	12,627	21.0	6,679	22.1	
Transmission Category (Unadjusted) Male-to-male sexual contact 30,440 50.7 14,691 48.7 Injection drug use 2,294 3.8 1,608 5.3 Male-to-male sexual contact and injection drug use 1,877 3.1 1,207 4.0 Heterosexual contact ² 10,058 16.7 5,616 18.6 Adult Other ³ 569 0.9 289 1.0 Perinatal/other pediatric ⁴ 73 0.1 20 0.1 Unknown 14,762 24.6 6,744 22.4 Male-to-male sexual contact 37,044 61.7 17,696 58.6 Injection drug use 3,360 5.6 2,214 7.3 Male-to-male sexual contact and injection drug use 2,314 3.9 1,451 4.8 Heterosexual contact ² 15,739 26.2 8,338 27.6 Adult Other ³ 569 0.9 289 1.0	50-59	15,792	26.3	9,762	32.4	
Male-to-male sexual contact 30,440 50.7 14,691 48.7 Injection drug use 2,294 3.8 1,608 5.3 Male-to-male sexual contact and injection drug use 1,877 3.1 1,207 4.0 Heterosexual contact ² 10,058 16.7 5,616 18.6 Adult Other ³ 569 0.9 289 1.0 Perinatal/other pediatric ⁴ 73 0.1 20 0.1 Unknown 14,762 24.6 6,744 22.4 Transmission Category (Adjusted) ⁵ 3360 5.6 2,214 7.3 Male-to-male sexual contact 37,044 61.7 17,696 58.6 Injection drug use 3,360 5.6 2,214 7.3 Male-to-male sexual contact 33,360 5.6 2,214 7.3 Male-to-male sexual contact and injection drug use 2,314 3.9 1,451 4.8 Heterosexual contact ² 15,739 26.2 8,338 27.6 Adult Other ³ 569	60+	10,461	17.4	6,748	22.4	
Injection drug use 2,294 3.8 1,608 5.3 Male-to-male sexual contact and injection drug use 1,877 3.1 1,207 4.0 Heterosexual contact ² 10,058 16.7 5,616 18.6 Adult Other ³ 569 0.9 289 1.0 Perinatal/other pediatric ⁴ 73 0.1 20 0.1 Unknown 14,762 24.6 6,744 22.4 Transmission Category (Adjusted) ⁵ 58.6 Male-to-male sexual contact 37,044 61.7 17,696 58.6 Injection drug use 3,360 5.6 2,214 7.3 Male-to-male sexual contact 3,360 5.6 2,214 7.3 Male-to-male sexual contact and injection drug use 2,314 3.9 1,451 4.8 Heterosexual contact ² 15,739 26.2 8,338 27.6 Adult Other ³ 569 0.9 289 1.0	Transmission Category (Unadjusted)					
Male-to-male sexual contact and injection drug use 1,877 3.1 1,207 4.0 Heterosexual contact ² 10,058 16.7 5,616 18.6 Adult Other ³ 569 0.9 289 1.0 Perinatal/other pediatric ⁴ 73 0.1 20 0.1 Unknown 14,762 24.6 6,744 22.4 Transmission Category (Adjusted) ⁵ 569 5.616 18.6 Male-to-male sexual contact 37,044 61.7 17,696 58.6 Injection drug use 3,360 5.6 2,214 7.3 Male-to-male sexual contact and injection drug use 2,314 3.9 1,451 4.8 Heterosexual contact ² 15,739 26.2 8,338 27.6 Adult Other ³ 569 0.9 289 1.0	Male-to-male sexual contact	30,440	50.7	14,691	48.7	
Heterosexual contact210,05816.75,61618.6Adult Other35690.92891.0Perinatal/other pediatric4730.1200.1Unknown14,76224.66,74422.4Transmission Category (Adjusted)5Male-to-male sexual contact37,04461.717,69658.6Injection drug use3,3605.62,2147.3Male-to-male sexual contact and injection drug use2,3143.91,4514.8Heterosexual contact215,73926.28,33827.6Adult Other35690.92891.0	Injection drug use	2,294	3.8	1,608	5.3	
Adult Other35690.92891.0Perinatal/other pediatric4730.1200.1Unknown14,76224.66,74422.4Transmission Category (Adjusted)5Male-to-male sexual contact37,04461.717,69658.6Injection drug use3,3605.62,2147.3Male-to-male sexual contact and injection drug use2,3143.91,4514.8Heterosexual contact215,73926.28,33827.6Adult Other35690.92891.0	Male-to-male sexual contact and injection drug use	1,877	3.1	1,207	4.0	
Perinatal/other pediatric ⁴ 73 0.1 20 0.1 Unknown 14,762 24.6 6,744 22.4 Transmission Category (Adjusted) ⁵ V V V Male-to-male sexual contact 37,044 61.7 17,696 58.6 Injection drug use 3,360 5.6 2,214 7.3 Male-to-male sexual contact and injection drug use 2,314 3.9 1,451 4.8 Heterosexual contact ² 15,739 26.2 8,338 27.6 Adult Other ³ 569 0.9 289 1.0	Heterosexual contact ²	10,058	16.7	5,616	18.6	
Unknown 14,762 24.6 6,744 22.4 Transmission Category (Adjusted) ⁵ 22.4 Male-to-male sexual contact 37,044 61.7 17,696 58.6 Injection drug use 3,360 5.6 2,214 7.3 Male-to-male sexual contact and injection drug use 2,314 3.9 1,451 4.8 Heterosexual contact ² 15,739 26.2 8,338 27.6 <th<< td=""><td>Adult Other³</td><td>569</td><td>0.9</td><td>289</td><td>1.0</td></th<<>	Adult Other ³	569	0.9	289	1.0	
Transmission Category (Adjusted) ⁵ Male-to-male sexual contact 37,044 61.7 17,696 58.6 Injection drug use 3,360 5.6 2,214 7.3 Male-to-male sexual contact and injection drug use 2,314 3.9 1,451 4.8 Heterosexual contact ² 15,739 26.2 8,338 27.6 Adult Other ³ 569 0.9 289 1.0	Perinatal/other pediatric ⁴	73	0.1	20	0.1	
Male-to-male sexual contact 37,044 61.7 17,696 58.6 Injection drug use 3,360 5.6 2,214 7.3 Male-to-male sexual contact and injection drug use 2,314 3.9 1,451 4.8 Heterosexual contact ² 15,739 26.2 8,338 27.6 Adult Other ³ 569 0.9 289 1.0	Unknown	14,762	24.6	6,744	22.4	
Injection drug use 3,360 5.6 2,214 7.3 Male-to-male sexual contact and injection drug use 2,314 3.9 1,451 4.8 Heterosexual contact ² 15,739 26.2 8,338 27.6 Adult Other ³ 569 0.9 289 1.0	Transmission Category (Adjusted) ⁵					
Male-to-male sexual contact and injection drug use 2,314 3.9 1,451 4.8 Heterosexual contact ² 15,739 26.2 8,338 27.6 Adult Other ³ 569 0.9 289 1.0	Male-to-male sexual contact	37,044	61.7	17,696	58.6	
Heterosexual contact ² 15,739 26.2 8,338 27.6 Adult Other ³ 569 0.9 289 1.0	Injection drug use	3,360	5.6	2,214	7.3	
Adult Other ³ 569 0.9 289 1.0	Male-to-male sexual contact and injection drug use	2,314	3.9	1,451	4.8	
	Heterosexual contact ²	15,739	26.2	8,338	27.6	
	Adult Other ³	569	0.9	289	1.0	
Perinatal/other pediatric4730.1200.1	Perinatal/other pediatric ⁴	73	0.1	20	0.1	

* Percentages may not add up to 100% due to rounding. 1. Persons whose infection was ever classified as stage 3 (AIDS). 2. Heterosexual contact: Defined as sexual contact with someone of the opposite sex with known risk such as injection drug use, bisexual male (applies to females only), person with hemophilia/coagulation disorder, transfusion recipient with HIV documentation, and or person with AIDS or documented HIV. 3. Includes perinatal exposure current age \geq 13, hemophilia, blood transfusion. 4. Perinatal/other pediatric: cases<13 born to HIV-infected mother, and cases <13 with missing risk. 5. Adjusted for missing risk using multiple imputation methods.

Table 6. Persons living with HIV (PLWH), and PLWH ever stage 3 (AIDS), Cis-Gender Males, Georgia, as of 12/31/2020

	PL	WН	Ever Stage	2 3 (AIDS) ¹
	N	%*	N	%*
Total	44,459	100.0	22,488	100.0
Race/Ethnicity				
Black/Non Hispanic	29,545	65.4	14,951	66.1
White/Non Hispanic	8,910	19.7	4,415	19.5
Hispanic/Latino, Any Race	3,616	8.0	1,818	8.0
American Indian/Alaska Native	24	0.1	8	0.0
Asian/Native Hawaiian/Pacific Islander	239	0.5	94	0.4
Multiple races	2,125	4.7	1,202	5.3
Current Age Group (Years)				
<13	39	0.1	12	0.1
13-19	203	0.5	27	0.1
20-29	5,579	12.4	1,261	5.6
30-39	11,290	25.0	4,308	19.1
40-49	8,885	19.7	4,742	21.0
50-59	11,714	25.9	7,338	32.5
60+	7,439	16.5	4,923	21.8
Transmission Category (Unadjusted)				
Male-to-male sexual contact	29,800	66.0	14,407	63.7
Injection drug use	1,271	2.8	923	4.1
Male-to-male sexual contact and injection drug use	1,848	4.1	1,190	5.3
Heterosexual contact ²	2,719	6.0	1,675	7.4
Adult Other ³	273	0.6	139	0.6
Perinatal/other pediatric ⁴	34	0.1	10	0.0
Unknown	9,211	20.4	4,268	18.9
Transmission Category (Adjusted) ⁵				
Male-to-male sexual contact	36,389	80.6	17,404	77.0
Injection drug use	1,728	3.8	1,199	5.3
Male-to-male sexual contact and injection drug use	2,284	5.1	1,433	6.3
Heterosexual contact ²	3,763	8.3	2,304	10.2
Adult Other ³	273	0.6	139	0.6
Perinatal/other pediatric ⁴	34	0.1	10	0.0

* Percentages may not add up to 100% due to rounding. 1. Persons whose infection was ever classified as stage 3 (AIDS). 2. Heterosexual contact: Defined as sexual contact with someone of the opposite sex with known risk such as injection drug use, bisexual male (applies to females only), person with hemophilia/coagulation disorder, transfusion recipient with HIV documentation, and or person with AIDS or documented HIV. 3. Includes perinatal exposure current age \geq 13, hemophilia, blood transfusion. 4. Perinatal/other pediatric: cases <13 born to HIV-infected mother, and cases <13 with missing risk. 5. Adjusted for missing risk using multiple imputation methods.

Table 7. Persons living with HIV (PLWH), and PLWH ever stage 3 (AIDS), Cis-Gender Females, Georgia, as of 12/31/2020

	PLW	/H	Ever Stage 3 (AIDS) ¹		
	Ν	%*	N	%*	
Total	13,892	100.0	7,182	100.0	
Race/Ethnicity					
Black/Non Hispanic	10,860	77.0	5,688	78.9	
White/Non Hispanic	1,504	10.7	692	9.6	
Hispanic/Latino, Any Race	820	5.8	406	5.6	
American Indian/Alaska Native	4	0.0	3	0.0	
Asian/Native Hawaiian/Pacific Islander	81	0.6	24	0.3	
Multiple races	623	4.4	369	5.1	
Current Age Group (Years)					
<13	42	0.3	10	0.1	
13-19	96	0.7	16	0.2	
20-29	956	6.8	247	3.4	
30-39	2,468	17.5	920	12.8	
40-49	3,584	25.4	1,853	25.7	
50-59	3,978	28.2	2,366	32.8	
60+	2,981	21.1	1,798	24.9	
Transmission Category (Unadjusted)					
Injection drug use	1,017	7.2	682	9.5	
Heterosexual contact ²	7,317	51.9	3,932	54.5	
Adult Other ³	291	2.1	146	2.0	
Perinatal/other pediatric ⁴	39	0.3	10	0.1	
Unknown	5,446	38.6	2,441	33.9	
Transmission Category (Adjusted) ⁵					
Injection drug use	1,623	11.5	1,010	14.0	
Heterosexual contact ²	11,935	84.6	6,015	83.4	
Adult Other ³	291	2.1	146	2.0	
Perinatal/other pediatric ⁴	39	0.3	10	0.1	

* Percentages may not add up to 100% due to rounding. 1. Persons whose infection was ever classified as stage 3 (AIDS). 2. Heterosexual contact: Defined as sexual contact with someone of the opposite sex with known risk such as injection drug use, bisexual male (applies to females only), person with hemophilia/coagulation disorder, transfusion recipient with HIV documentation, and or person with AIDS or documented HIV. 3. Includes perinatal exposure current age \geq 13, hemophilia, blood transfusion. 4. Perinatal/other pediatric: cases <13 born to HIV-infected mother, and cases <13 with missing risk. 5. Adjusted for missing risk using multiple imputation methods. Table 8. Persons living with HIV (PLWH), and PLWH ever stage 3 (AIDS), Transgender Persons, Georgia, as of 12/31/2020

	PLW	н _	Ever Stage 3 (AIDS) ¹		
	Ν	%*	N	%*	
Total	683	100.0	311	100.0	
Gender Identity					
Transgender Woman	653	95.6	298	95.8	
Transgender Man	30	4.4	13	4.2	
Race/Ethnicity					
Black/Non Hispanic	538	78.8	244	78.5	
White/Non Hispanic	39	5.7	13	4.2	
Hispanic/Latino, Any Race	73	10.7	39	12.5	
American Indian/Alaska Native	0	0.0	0	0.0	
Asian/Native Hawaiian/Pacific Islander	0	0.0	0	0.0	
Multiple races	33	4.8	15	4.8	
Current Age Group (Years)					
13-19	2	0.3	1	0.3	
20-29	163	23.9	45	14.5	
30-39	298	43.6	126	40.5	
40-49	126	18.4	73	23.5	
50-59	72	10.5	49	15.8	
60+	22	3.2	17	5.5	
Transmission Category (Unadjusted)					
Sexual contact ²	634	91.2	280	90.1	
Injection drug use	3	0.4	1	0.3	
Sexual contact and injection drug use	27	4.0	16	5.1	
Adult Other ³	4	0.6	3	1.0	
Unknown	26	3.8	11	3.5	
Transmission Category (Adjusted) ⁴					
Sexual contact ²	647	94.6	290	93.2	
Injection drug use	5	0.7	2	0.6	
Sexual contact and injection drug use	28	4.1	16	5.3	
Adult Other ³	4	0.6	3	1.0	

* Percentages may not add up to 100% due to rounding. 1. Persons whose infection was ever classified as stage 3 (AIDS). 2. Includes sex with male and probable heterosexual transmission as noted in medical chart 3. Includes perinatal exposure current age \geq 13, hemophilia, blood transfusion.4. Adjusted for missing risk using multiple imputation methods.

HIV Diagnoses and Persons Living with HIV by Public Health District

Table 9. HIV Diagnoses and Persons Living with HIV, District 1-1 (Rome), Georgia, 2020

Data for 2020 diagnoses should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing

	HIV diag	noses	PLWH as of 12	/31/2020
	N	%*	N	%*
Total	53	100.0	1,239	100.0
Gender Identity	00	100.0	1,200	100.0
Cisgender Male	38	71.7	896	72.3
Cisgender Female	14	26.4	339	27.4
Transgender Woman	<5		<5	
Transgender Man	0	0.0	0	0.0
Race/Ethnicity				
Black/Non Hispanic	28	52.8	506	40.8
White/Non Hispanic	21	39.6	557	45.0
Hispanic/Latino, Any Race	<5		104	8.4
American Indian/Alaska Native	0	0.0	0	0.0
Asian/Native Hawaiian/Pacific Islander	0	0.0	5	0.4
Multiple races	0	0.0	48	3.9
Age Group (at diagnosis for diagnosed,				
current for PLWH)				
<13	0	0.0	<5	
13-19	<5		9	0.7
20-29	19	35.8	115	9.3
30-39	13	24.5	216	17.4
40-49	8	15.1	282	22.8
50-59	8	15.1	353	28.5
60+	<5		263	21.2
Transmission Category (Unadjusted)				
Male-to-male sexual contact	23	43.4	515	41.6
Injection drug use	<5		92	7.4
Male-to-male sexual contact and injection drug use	<5		65	5.2
Heterosexual contact ¹	12	22.6	206	16.6
Adult Other ²	0	0.0	20	1.6
Perinatal/other pediatric ³	0	0.0	<5	
Unknown	13	24.5	340	27.4
Transmission Category (Adjusted) ⁴				
Male-to-male sexual contact	30	57.4	669	54.0
Injection drug use	<5		119	9.6
Male-to-male sexual contact and injection drug use	<5		78	6.3
Heterosexual contact ¹	17	32.5	333	26.9
Adult Other ²	0	0.0	20	1.6
Perinatal/other pediatric ³	0	0.0	<5	

Table 10. HIV Diagnoses and Persons Living with HIV, District 1-2 (Dalton), Georgia, 2020

Data for 2020 diagnoses should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing

	HIV di	agnoses	PLWH as of 12/31/2020		
	N	%*	N	%*	
Total	23	100.0	722	100.0	
Gender Identity					
Cisgender Male	17	73.9	566	78.4	
Cisgender Female	<5		147	20.4	
Transgender Woman	<5		5	0.7	
Transgender Man	0	0.0	0	0.0	
Race/Ethnicity					
Black/Non Hispanic	<5		136	18.8	
White/Non Hispanic	15	65.2	407	56.4	
Hispanic/Latino, Any Race	5	21.7	127	17.6	
American Indian/Alaska Native	0	0.0	0	0.0	
Asian/Native Hawaiian/Pacific Islander	0	0.0	<5		
Multiple races	0	0.0	35	4.8	
Age Group (at diagnosis for diagnosed, current for PLWH)					
<13	0	0.0	0	0.0	
13-19	<5		<5		
20-29	8	34.8	72	10.0	
30-39	9	39.1	122	16.9	
40-49	<5		175	24.2	
50-59	<5		202	28.0	
60+	0	0.0	148	20.5	
Transmission Category (Unadjusted)					
Male-to-male sexual contact	13	56.5	366	50.7	
Injection drug use	<5		33	4.6	
Male-to-male sexual contact and injection drug use	<5		48	6.6	
Heterosexual contact ¹	<5		100	13.9	
Adult Other ²	0	0.0	<5		
Perinatal/other pediatric ³	0	0.0	0	0.0	
Unknown	<5		171	23.7	
Transmission Category (Adjusted) ³					
Male-to-male sexual contact	14	59.1	447	62.0	
Injection drug use	<5		46	6.3	
Male-to-male sexual contact and injection drug use	<5		54	7.5	
Heterosexual contact ¹	5	22.2	156	21.6	
Adult Other ²	0	0.0	<5		
Perinatal/other pediatric ⁴	0	0.0	0	0.0	

* Percentages may not add up to 100% due to rounding 1. Heterosexual contact: Defined as sexual contact with someone of the opposite sex with known risk such as injection drug use, bisexual male (applies to females only), person with hemophilia/coagulation disorder, transfusion recipient with HIV documentation, and or person with AIDS or documented HIV. 2. Includes perinatal exposure current age \geq 13; hemophilia, blood transfusion. 3.

Perinatal/other pediatric: cases <13 born to HIV-infected mother, and cases <13 with missing risk. 4. Adjusted for missing risk using multiple imputation

 $2l_{\rm }$ methods. Adjusted subtotals may be different from unadjusted subtotals due to rounding

Table 11. HIV Diagnoses and Persons Living with HIV, District 2 (Gainesville), Georgia, 2020

Data for 2020 diagnoses should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing

48 100.0 93 100.0 Cisgender Male 33 68.8 679 70.5 Cisgender Female 13 27.1 27.3 28.3 Transgender Woman <5 9 0.9 Transgender Man 0 0.0 0 0 0 Race/Ethnicity 18 37.5 240 24.9 White/Non Hispanic 18 37.5 240 24.9 White/Non Hispanic 18 37.5 240 24.9 Mite/Non Hispanic 18 37.5 240 24.9 Mite/Non Hispanic 18 37.5 240 24.9 Agian/Native Havaiian/Pacific Islander <5 22 2.3 Multiple races <5 23 55 Pace Group (at diagnosis for diagnosed, current for pace datagnosis for diagnosed, current for pace datagnosis for diagnosed, current for pace datagnosis 24 2.3 S0-59 8 16.7 28 29.7 10.1 <th></th> <th>HIV di</th> <th>agnoses</th> <th colspan="2">PLWH as of 12/31/2020</th>		HIV di	agnoses	PLWH as of 12/31/2020	
48 100.0 93 100.0 Cisgender Male 33 68.8 679 70.5 Cisgender Female 13 27.1 27.3 28.3 Transgender Woman <5 9 0.9 Transgender Man 0 0.0 0 0 0 Race/Ethnicity 18 37.5 240 24.9 White/Non Hispanic 18 37.5 240 24.9 White/Non Hispanic 18 37.5 240 24.9 Mite/Non Hispanic 18 37.5 240 24.9 Mite/Non Hispanic 18 37.5 240 24.9 Agian/Native Havaiian/Pacific Islander <5 22 2.3 Multiple races <5 23 55 Pace Group (at diagnosis for diagnosed, current for pace datagnosis for diagnosed, current for pace datagnosis for diagnosed, current for pace datagnosis 24 2.3 S0-59 8 16.7 28 29.7 10.1 <th></th> <th>N</th> <th>%*</th> <th>N</th> <th>%*</th>		N	%*	N	%*
Clagender Male3368.867970.5Clagender Female1327.127328.3Transgender Woman-590.9Transgender Man00.00.00.0Race/Ethnick1837.524024.9Mihte/Non Hispanic1837.524024.9Mihte/Non Hispanic1837.524024.9Mihte/Non Hispanic612.5150156American Indian/Ataska Native00.0-5American Indian/Ataska Native00.0-5Multiple races-5222.3Multiple races-5535.5Age Group (at diagnosis for diagnosed, current for Privm)530.013-19-522423.330-39918.816.728629.730-39816.728629.730-40-5495.114et-or-male sexual contact2450.04042.017918.6495.116et-or-male sexual contact nd injection drug use-5495.116et-or-male sexual contact </th <th>Total</th> <th>48</th> <th>100.0</th> <th>963</th> <th>100.0</th>	Total	48	100.0	963	100.0
Consistent of Penale 13 27.1 273 28.3 Transgender Woman -5 9 0.9 Transgender Man 0 0.0 0.0 0.0 Race/Ethnicity 8 37.5 240 24.9 Black/Non Hispanic 18 37.5 240 24.9 Hispanic/Latino, Any Race 6 12.5 150 15.6 American Indian/Alaska Native 0 0.0 -5 Age Group fat diagnosis for diagnosed, current for pervers 22 2.3 Age Group fat diagnosis for diagnosed, current for pervers 26 9.0 0.0 0.0 0.0 0.0 10.1 30-39 9 18.8 17.3 18.0 202-20 41.7 97 10.1 30-39 8 16.7 264 29.7 30-49 5 49 5.1 9 18.8 16.7 18.9 16	Gender Identity				
Transgender Woman -5 9 0.9 Transgender Man 0 0.0 0 0.0 Race/Ethicity 37.5 240 24.9 Mhite/Non Hispanic 18 37.5 240 24.9 Mhite/Non Hispanic 18 37.5 240 24.9 Mite/Non Hispanic 18 37.5 240 24.9 Mite/Non Hispanic 18 37.5 240 24.9 American Indian/Alaska Native 0 0.0 22 2.3 Age Group (at diagnosis for diagnosed, current for preview) 5 22 2.3 20.2 20 41.7 9.7 10.1 30.3 18.0 17.3 18.0 30-39 9 18.8 17.3 18.0 18.0 17.3 18.0 20.2 9 18.8 16.7 226 29.7 18.0 30-39 8 16.7 25 49 <td>Cisgender Male</td> <td>33</td> <td>68.8</td> <td>679</td> <td>70.5</td>	Cisgender Male	33	68.8	679	70.5
Transpender Man 0 0.0 0 0.0 Race/Ethnicity Number Non Hispanic 18 37.5 240 24.9 Mhile/Non Hispanic 18 37.5 247 48.9 Hispanic/Latino, Any Race 6 12.5 150 156 American Indian/Alaska Native 0 0.0 -5 - Saian/Native Hawaiian/Pacific Islander <5 53 5.5 Age Group (at diagnosis for diagnosed, current for PLWH) 53 0.0 13.19 <5 <5 0.4 10.1 30-39 9 18.8 17.3 18.0 40-49 <5 <5 0.4 50-59 8 16.7 286 29.7 50+ -5 41 4.3 Male-to-male sexual contact 24 50.0 40.4 42.0 10-14 13 16.7 158 16.4 40-14 10	Cisgender Female	13	27.1	273	28.3
Accele Ethnicity Biack/Non Hispanic 18 37.5 240 24.9 Minite/Non Hispanic 18 37.5 471 48.9 Hispanic/Latino, Any Race 6 12.5 150 150 American Indian/Alaska Native 6 12.5 150 5 American Indian/Alaska Native 65 22 2.3 Multiple races -5 53 5.5 Age Group (at diagnosis for diagnosed, current for runn) 45 0.4 20-29 0 0.0 0 0.0 13-19 -5 22 2.3 30-39 9 18.8 173 18.0 20-29 20 41.7 97 10.1 30-39 9 18.8 173 18.0 50-59 8 16.7 179 18.6 Transmission Category (Unadjusted) - - 49 5.1 Male-to-male sexual contact 24 50.0 <	Transgender Woman	<5		9	0.9
Black/Non Hispanic 18 37.5 240 24.9 White/Non Hispanic 18 37.5 471 48.9 Hispanic/Latino, Any Race 6 12.5 150 15.6 American Indian/Alaska Native 0 0.0 -5 22 2.3 Asian/Native Hawaiian/Pacific Islander -5 22 2.3 Asian/Native Hawaiian/Pacific Islander -5 22 2.3 Asian/Native Hawaiian/Pacific Islander -5 22 2.3 Age foroup (at diagnosis for diagnosed, current for provin) 5 0.0 13.19 -5 - 5 0.4 40-49 -5 - 224 23.3 50-59 8 16.7 286 29.7 60+ -5 17.9 18.6 Transmission Category (Unadjusted) -5 41 4.3 Male-to-male sexual contact 16 5	Transgender Man	0	0.0	0	0.0
White/Non Hispanic 18 37.5 471 48.9 Hispanic/Latino, Any Race 6 12.5 150 15.6 American Indian/Alaska Native 0 0.0 -5 22 2.3 Asian/Native Hawaiian/Pacific Islander -5 53 5.5 Age Group (at diagnosis for diagnosed, current for preven) 53 0.0 13-19 -5 0.0 0.0 30-39 9 18.8 173 18.0 13.1 30-39 9 18.8 173 18.0 30-39 9 18.8 173 18.0 50-59 8 16.7 286 29.7 S0-4 49 5.1 18.6 Injection drug use -5 49 5.1 Male-to-male sexual contact 16 5.0 0.0 0.0 0.0 Injection drug use -5 49	Race/Ethnicity				
Hispanic/Latino, Any Race 6 12.5 150 15.6 American Indian/Alaska Native 0 0.0 -5 - 22 2.3 Asian/Native Hawaiian/Pacific Islander -5 - 53 5.5 Age Group (at diagnosis for diagnosed, current for prover) - 53 5.5 Age Group (at diagnosis for diagnosed, current for prover) - - 50 0.0 0.0 13-19 -5 - 50 0.4 0.0 0.0 0.0 13-19 -5 - 5 0.4 0.0 0.0 0.0 20-29 20 41.7 97 10.1 0.3 0.0 <t< td=""><td>Black/Non Hispanic</td><td>18</td><td>37.5</td><td>240</td><td>24.9</td></t<>	Black/Non Hispanic	18	37.5	240	24.9
American Indian/Alaska Native 0 0.0 -5 Asian/Native Hawaiian/Pacific Islander -5 22 2.3 Multiple races -5 53 5.5 Age Group (at diagnosis for diagnosed, current for provid) 53 0.0 <13	White/Non Hispanic	18	37.5	471	48.9
Asian/Native Hawaiian/Pacific Islander < 5 $ 22$ 2.3 Multiple races < 5 $ 53$ 5.5 Age Group (at diagnosis for diagnosed, current for pr.W.) < 3 0 0.0 0 0.0 <13 0 0.0 0.0 0.0 0.0 0.0 20.29 20 41.7 97 10.1 30.39 9 18.8 17.3 18.0 40.49 < 5 $$ 224 23.3 20.5 <th< td=""><td>Hispanic/Latino, Any Race</td><td>6</td><td>12.5</td><td>150</td><td>15.6</td></th<>	Hispanic/Latino, Any Race	6	12.5	150	15.6
Multiple races -5 53 5.5 Age Group (at diagnosis for diagnosed, current for PHWH)	American Indian/Alaska Native	0	0.0	<5	
Age Group (at diagnosis for diagnosed, current for PHWH) 0 0.0 0 0.0 <13	Asian/Native Hawaiian/Pacific Islander	<5		22	2.3
Puwhi Image: stress of the stres	Multiple races	<5		53	5.5
<1300.00.00.013-19<5	Age Group (at diagnosis for diagnosed, current for PLWH)				
20-29 20 41.7 97 10.1 30-39 9 18.8 173 18.0 40-49 ~5 224 23.3 50-59 8 16.7 286 29.7 80+ 179 18.6 29.7 80+ 179 18.6 29.7 80+ 179 18.6 29.7 80+ 179 18.6 29.7 B10+ 179 18.6 29.7 B2 41 42.0 42.0 Injection drug use <5	<13	0	0.0	0	0.0
30-39918.817318.040-49<5	13-19	<5		<5	0.4
40-49<522423.350-59816.728629.750+<5	20-29	20	41.7	97	10.1
50-59816.728629.760+<5	30-39	9	18.8	173	18.0
60+<517918.6Transmission Category (Unadjusted)Male-to-male sexual contact2450.040442.0Injection drug use<5	40-49	<5		224	23.3
Transmission Category (Unadjusted) 24 50.0 404 42.0 Male-to-male sexual contact 24 50.0 404 42.0 Injection drug use <5	50-59	8	16.7	286	29.7
Male-to-male sexual contact 24 50.0 404 42.0 Injection drug use <5 $$ 41 4.3 Male-to-male sexual contact and injection drug use <5 $$ 49 5.1 Heterosexual contact ¹ 8 16.7 158 16.4 Adult Other ² 0 0.0 9 0.9 Perinatal/other pediatric ³ 0 0.0 0 0.0 Unknown 14 29.2 302 31.4 Male-to-male sexual contact 31 64.0 534 55.5 Injection drug use <5 $$ 64 6.7 Male-to-male sexual contact and injection drug use <5 $$ 64 6.7 Male-to-male sexual contact and injection drug use <5 $$ 58 6.0 Male-to-male sexual contact and injection drug use <5 $$ 58 6.0 Male-to-male sexual contact ¹ 13 27.5 272 28.3 Male-to-male sexual contact ¹ 0 0.0 9	60+	<5		179	18.6
Injection drug use<5414.3Male-to-male sexual contact and injection drug use<5	Transmission Category (Unadjusted)				
Male-to-male sexual contact and injection drug use <5 49 5.1 Heterosexual contact ¹ 8 16.7 158 16.4 Adult Other ² 0 0.0 9 0.9 Perinatal/other pediatric ³ 0 0.0 0 0.0 Unknown 14 29.2 302 31.4 Transmission Category (Adjusted) ⁴ Male-to-male sexual contact 31 64.0 534 55.5 Injection drug use <5	Male-to-male sexual contact	24	50.0	404	42.0
Heterosexual contact ¹ 8 16.7 158 16.4 Adult Other ² 0 0.0 9 0.9 Perinatal/other pediatric ³ 0 0.0 0 0.0 Unknown 14 29.2 302 31.4 Transmission Category (Adjusted) ⁴ 7 64 55.5 Injection drug use <5	Injection drug use	<5		41	4.3
Adult Other ² 0 0.0 9 0.9 Perinatal/other pediatric ³ 0 0.0 0 0.0 Unknown 14 29.2 302 31.4 Transmission Category (Adjusted) ⁴ 7 7 64.0 55.5 Male-to-male sexual contact 31 64.0 534 55.5 Injection drug use <5	Male-to-male sexual contact and injection drug use	<5		49	5.1
Perinatal/other pediatric ³ 0 0.0 0 0.0 Unknown 14 29.2 302 31.4 Transmission Category (Adjusted) ⁴ Male-to-male sexual contact 31 64.0 534 55.5 Injection drug use <5	Heterosexual contact ¹	8	16.7	158	16.4
Unknown 14 29.2 302 31.4 Transmission Category (Adjusted) ¹⁴ Transmission Category (Adjusted) ¹⁴ State	Adult Other ²	0	0.0	9	0.9
Transmission Category (Adjusted) ⁴ Male-to-male sexual contact 31 64.0 534 55.5 Injection drug use <5	Perinatal/other pediatric ³	0	0.0	0	0.0
Male-to-male sexual contact 31 64.0 534 55.5 Injection drug use <5	Unknown	14	29.2	302	31.4
Injection drug use <5 64 6.7 Male-to-male sexual contact and injection drug use <5	Transmission Category (Adjusted)4				
Male-to-male sexual contact and injection drug use<558 6.0 Heterosexual contact ¹ 1327.527228.3Adult Other ² 0 0.0 9 0.9	Male-to-male sexual contact	31	64.0	534	55.5
Heterosexual contact ¹ 13 27.5 272 28.3 Adult Other ² 0 0.0 9 0.9	Injection drug use	<5		64	6.7
Adult Other ² 0 0.0 9 0.9	Male-to-male sexual contact and injection drug use	<5		58	6.0
	Heterosexual contact ¹	13	27.5	272	28.3
Perinatal/other pediatric ³ 0 0.0 0.0 0.0	Adult Other ²	0	0.0	9	0.9
	Perinatal/other pediatric ³	0		0	

Table 12. HIV Diagnoses and Persons Living with HIV, District 3-1 (Cobb/Douglas), Georgia, 2020

Data for 2020 diagnoses should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing

	HIV dia	ignoses	PLWH as of 2	12/31/2020
	N	%*	N	%*
Total	160	100.0	4,311	100.0
Gender Identity			.,	
Cisgender Male	126	78.8	3,296	76.5
Cisgender Female	29	18.1	957	22.2
Transgender Woman	5	3.1	49	1.1
Transgender Man	0	0.0	<5	
Race/Ethnicity				
Black/Non Hispanic	107	66.9	2,719	63.1
White/Non Hispanic	34	21.3	844	19.6
Hispanic/Latino, Any Race	15	9.4	455	10.6
American Indian/Alaska Native	0	0.0	<5	
Asian/Native Hawaiian/Pacific Islander	<5		17	0.4
Multiple races	<5		224	5.2
Age Group (at diagnosis for diagnosed, current for PLWH)				
<13	0	0.0	5	0.1
13-19	5	3.1	12	0.3
20-29	69	43.1	539	12.5
30-39	56	35.0	1,134	26.3
40-49	19	11.9	961	22.3
50-59	7	4.4	1,064	24.7
60+	<5		595	13.8
Transmission Category (Unadjusted)				
Male-to-male sexual contact	92	57.5	2,358	54.7
Injection drug use	<5		122	2.8
Male-to-male sexual contact and injection drug use	<5		122	2.8
Heterosexual contact ¹	26	16.3	750	17.4
Adult Other ²	0	0.0	40	0.9
Perinatal/other pediatric ³	0	0.0	5	0.1
Unknown	37	23.1	914	21.2
Transmission Category (Adjusted) ⁴				
Male-to-male sexual contact	113	70.4	2,820	65.4
Injection drug use	5	2.9	184	4.3
Male-to-male sexual contact and injection drug use	<5		150	3.5
Heterosexual contact ¹	39	24.3	1,060	24.6
Adult Other ²	0	0.0	40	0.9
Perinatal/other pediatric ³	0	0.0	5	0.1

Table 13. HIV Diagnoses and Persons Living with HIV, District 3-2 (Fulton), Georgia, 2020

Data for 2020 diagnoses should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV

	HIV diagnoses		PLWH as of	12/31/2020
	N	%*	N	%*
Total	481	100.0	16,377	100.0
Gender Identity	101	100.0	10,011	100.0
Cisgender Male	404	84.0	13602	83.1
Cisgender Female	62	12.9	2520	15.4
Transgender Woman	15	3.1	211	1.3
Transgender Man	0	0.0	7	0.0
Race/Ethnicity				
Black/Non Hispanic	384	79.8	11901	72.7
White/Non Hispanic	55	11.4	2494	15.2
Hispanic/Latino, Any Race	28	5.8	960	5.9
American Indian/Alaska Native	<5		8	0.0
Asian/Native Hawaiian/Pacific Islander	<5		59	0.4
Multiple races	8	1.7	739	4.5
Age Group (at diagnosis for diagnosed, current for PLWH)				
<13	0	0.0	11	0.1
13-19	18	3.7	41	0.3
20-29	195	40.5	1679	10.3
30-39	148	30.8	4178	25.5
40-49	54	11.2	3449	21.1
50-59	48	10.0	4250	26.0
60+	18	3.7	2763	16.9
Transmission Category (Unadjusted)				
Male-to-male sexual contact	324	67.4	10109	61.7
Injection drug use	<5		620	3.8
Male-to-male sexual contact and injection drug use	8	1.7	614	3.7
Heterosexual contact ¹	74	15.4	1910	11.7
Adult Other ²	0	0.0	97	0.6
Perinatal/other pediatric ³	0	0.0	7	0.0
Unknown	72	15.0	3020	18.4
Transmission Category (Adjusted) ⁴				
Male-to-male sexual contact	362	75.3	11703	71.5
Injection drug use	7	1.5	812	5.0
Male-to-male sexual contact and injection drug use	9	2.0	721	4.4
Heterosexual contact ¹	98	20.4	2818	17.2
Adult Other ²	0	0.0	97	0.6
Perinatal/other pediatric ³	0	0.0	7	0.0

Table 14. HIV Diagnoses and Persons Living with HIV, District 3-3 (Clayton), Georgia, 2020

Data for 2020 diagnoses should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing

	HIV dia	gnoses	PLWH as of	12/31/2020
	Ν	%*	N	%*
Total	113	100.0	3,056	100.0
Gender Identity				
Cisgender Male	86	76.1	2,206	72.2
Cisgender Female	24	21.2	796	26.0
Transgender Woman	<5		49	1.6
Transgender Man	0	0.0	<5	
Race/Ethnicity				
Black/Non Hispanic	97	85.8	2,537	83.0
White/Non Hispanic	6	5.3	117	3.8
Hispanic/Latino, Any Race	8	7.1	198	6.5
American Indian/Alaska Native	0	0.0	<5	
Asian/Native Hawaiian/Pacific Islander	0	0.0	25	0.8
Multiple races	<5		146	4.8
Age Group (at diagnosis for diagnosed,				
current for PLWH) <13	0	0.0	6	0.2
13-19	<5		14	0.2
20-29	55	48.7	481	15.7
30-39	33	27.4	826	27.0
40-49	13	11.5	639	20.9
50-59	10	8.9	695	20.3
60+	<5		395	12.9
Transmission Category (Unadjusted)				12.0
Male-to-male sexual contact	67	59.3	1,616	52.9
Injection drug use	<5		91	3.0
Male-to-male sexual contact and injection drug	0	0.0	70	2.3
use Heterosexual contact ¹	21	18.6	560	18.3
Adult Other ²	0	0.0	35	1.1
Perinatal/other pediatric ³	0	0.0	6	0.2
Unknown	24	21.2	678	22.2
Transmission Category (Adjusted) ⁴				
Male-to-male sexual contact	79	70.0	1,904	62.3
Injection drug use	<5		135	4.4
Male-to-male sexual contact and injection drug	<5		87	2.9
use Heterosexual contact ¹	29	26.0	861	28.2
Adult Other ²	0	0.0	35	1.1
Perinatal/other pediatric ³	0	0.0	6	0.2

Table 15. HIV Diagnoses and Persons Living with HIV, District 3-4 (East Metro), Georgia, 2020

Data for 2020 diagnoses should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing

	HIV dia	gnoses	PLWH as of	12/31/2020
	N	%*	N	%*
Fotal	184	100.0	4,532	100.0
Gender Identity				
Cisgender Male	144	77.8	3,271	72.2
Cisgender Female	33	17.8	1,206	26.6
Fransgender Woman	7	3.8	42	0.9
Fransgender Man	<5	0.5	6	0.1
Race/Ethnicity				
Black/Non Hispanic	107	57.8	2,760	60.9
White/Non Hispanic	21	11.4	714	15.8
Hispanic/Latino, Any Race	51	27.6	704	15.5
American Indian/Alaska Native	0	0.0	0	0.0
Asian/Native Hawaiian/Pacific Islander	<5	2.2	68	1.5
Multiple races	0	0.0	206	4.5
Age Group (at diagnosis for diagnosed,				
current for PLWH)				
<13	0	0.0	7	0.2
13-19	17	9.2	27	0.6
20-29	83	44.9	575	12.7
30-39	41	22.2	1,051	23.2
10-49	27	14.6	1,028	22.7
50-59	10	5.4	1,194	26.3
\$0+	7	3.8	650	14.3
Transmission Category (Unadjusted)				
Male-to-male sexual contact	122	65.9	2,243	49.5
njection drug use	<5	1.1	121	2.7
Male-to-male sexual contact and injection	0	0.0	87	1.9
Heterosexual contact ¹	20	10.8	807	17.8
Adult Other ²	0	0.0	44	1.0
Perinatal/other pediatric ³	0	0.0	7	0.2
Jnknown	41	22.2	1,223	27.0
Fransmission Category (Adjusted) ⁴				
Male-to-male sexual contact	137	74.2	2,764	61.0
njection drug use	<5	2.2	204	4.5
Male-to-male sexual contact and injection	<5	0.3	122	2.7
drug use	41	22.3	1,311	28.9
leterosexual contact			· , - · ·	_0.0
Heterosexual contact ¹ Adult Other ²	0	0.0	44	1.0

Table 16. HIV Diagnoses and Persons Living with HIV, District 3-5 (DeKalb), Georgia, 2020

Data for 2020 diagnoses should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing

	HIV dia	gnoses	PLWH as of 12/31/20	
	N	%*	N	%*
Total	278	100.0	9,974	100.0
Gender Identity	-		- , -	
Cisgender Male	213	76.6	7,942	79.6
Cisgender Female	57	20.5	1,880	18.8
Transgender Woman	8	2.9	127	1.3
Transgender Man	0	0.0	5	0.1
Race/Ethnicity				
Black/Non Hispanic	214	77.0	7,103	71.2
White/Non Hispanic	27	9.7	1,546	15.5
Hispanic/Latino, Any Race	25	9.0	701	7.0
American Indian/Alaska Native	<5		<5	
Asian/Native Hawaiian/Pacific Islander	<5		76	0.8
Multiple races	<5		433	4.3
Age Group (at diagnosis for diagnosed, current for PLWH)				
<13	<5		14	0.1
13-19	10	3.6	43	0.4
20-29	113	40.6	1,011	10.1
30-39	75	27.0	2,429	24.4
40-49	38	13.7	2,155	21.6
50-59	35	12.6	2,650	26.6
60+	6	2.2	1,671	16.8
Transmission Category (Unadjusted)				
Male-to-male sexual contact	163	58.6	5,900	59.2
Injection drug use	6	2.2	246	2.5
Male-to-male sexual contact and injection drug use	5	1.8	299	3.0
Heterosexual contact ¹	36	13.0	1,368	13.7
Adult Other ²	0	0.0	74	0.7
Perinatal/other pediatric ³	0	0.0	12	0.1
Unknown	68	24.5	2,075	20.8
Transmission Category (Adjusted) ⁴				
Male-to-male sexual contact	189	67.9	6,913	69.3
Injection drug use	10	3.6	392	3.9
Male-to-male sexual contact and injection drug use	6	2.1	371	3.7
Heterosexual contact ¹	69	24.6	2,099	21.0
Adult Other ²	0	0.0	74	0.7
Perinatal/other pediatric ³	0	0.0	12	0.1

Table 17. HIV Diagnoses and Persons Living with HIV, District 4 (LaGrange), Georgia, 2020

Data for 2020 diagnoses should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing

	HIV di	agnoses	PLWH as of 12/31/		
	N	%*	Ν	%*	
Total	96	100.0	2,529	100.0	
Gender Identity					
Cisgender Male	74	77.1	1,821	72.0	
Cisgender Female	18	18.8	679	26.8	
Transgender Woman	<5		25	1.0	
Transgender Man	0	0.0	<5		
Race/Ethnicity					
Black/Non Hispanic	70	72.9	1,653	65.4	
White/Non Hispanic	16	16.7	544	21.5	
Hispanic/Latino, Any Race	6	6.3	157	6.2	
American Indian/Alaska Native	0	0.0	<5		
Asian/Native Hawaiian/Pacific Islander	<5		7	0.3	
Multiple races	<5		136	5.4	
Age Group (at diagnosis for diagnosed, current for PLWH)					
<13	0	0.0	5	0.2	
13-19	5	5.2	25	1.0	
20-29	40	41.7	321	12.7	
30-39	24	25.0	557	22.0	
40-49	15	15.6	519	20.5	
50-59	5	5.2	659	26.1	
60+	7	7.3	442	17.5	
Transmission Category (Unadjusted)					
Male-to-male sexual contact	52	54.2	1,154	45.6	
Injection drug use	0	0.0	103	4.1	
Male-to-male sexual contact and injection drug use	0	0.0	74	2.9	
Heterosexual contact ¹	21	21.9	478	18.9	
Adult Other ²	0	0.0	33	1.3	
Perinatal/other pediatric ³	0	0.0	5	0.2	
Unknown	23	24.0	682	27.0	
Transmission Category (Adjusted) ⁴					
Male-to-male sexual contact	68	70.4	1,455	57.5	
Injection drug use	<5		159	6.3	
Male-to-male sexual contact and injection drug use	<5		96	3.8	
Heterosexual contact ¹	25	25.8	752	29.8	
Adult Other ²	0	0.0	33	1.3	
Perinatal/other pediatric ³	0	0.0	5	0.2	

Table 18. HIV Diagnoses and Persons Living with HIV, District 5-1 (Dublin), Georgia, 2020

Data for 2020 diagnoses should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing

		gnoses	PLWH as of 12/31/20	
	N	%*	N	%*
Total	16	100.0	608	100.0
Gender Identity				
Cisgender Male	13	81.3	409	67.3
Cisgender Female	<5		195	32.1
Transgender Woman	<5		<5	
Transgender Man	0	0.0	0	0.0
Race/Ethnicity				
Black/Non Hispanic	15	93.8	443	72.9
White/Non Hispanic	<5		77	12.7
Hispanic/Latino, Any Race	0	0.0	50	8.2
American Indian/Alaska Native	0	0.0	0	0.0
Asian/Native Hawaiian/Pacific Islander	0	0.0	0	0.0
Multiple races	0	0.0	32	5.3
Age Group (at diagnosis for diagnosed, current for PLWH)				
<13	0	0.0	<5	
	<5		<5	
20-29	7	43.8	43	7.1
30-39	<5		100	16.4
40-49	<5		138	22.7
50-59	<5		188	30.9
60+	<5		136	22.4
Transmission Category (Unadjusted)				
Male-to-male sexual contact	8	50.0	149	24.5
Injection drug use	0	0.0	47	7.7
Male-to-male sexual contact and injection drug use	<5		20	3.3
Heterosexual contact ¹	<5		141	23.2
Adult Other ²	0	0.0	<5	
Perinatal/other pediatric ³	0	0.0	<5	
Unknown	5	31.3	246	40.5
Transmission Category (Adjusted) ³				
Male-to-male sexual contact	11	68.1	262	43.0
Injection drug use	<5		69	11.3
Male-to-male sexual contact and injection drug use	<5		28	4.6
Heterosexual contact ¹	<5		239	39.3
Adult Other ²	0	0.0	<5	
Perinatal/other pediatric ³	0	0.0	<5	

Table 19. HIV Diagnoses and Persons Living with HIV, District 5-2 (Macon), Georgia, 2020

Data for 2020 diagnoses should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing

		gnoses PLWH as of 12/31/2		12/21/2020
	N	%*	N N	%* %
Total				
Gender Identity	83	100.0	2,332	100.0
Cisgender Male	58	69.9	1,587	68.1
Cisgender Female	25	30.1	720	30.9
Transgender Woman	0	0.0	19	0.8
Transgender Man	0	0.0	0	0.0
Race/Ethnicity				
Black/Non Hispanic	65	78.3	1,748	75.0
White/Non Hispanic	14	16.9	343	14.7
Hispanic/Latino, Any Race	<5		99	4.2
American Indian/Alaska Native	0	0.0	<5	
Asian/Native Hawaiian/Pacific Islander	0	0.0	<5	
Multiple races	<5		112	4.8
Age Group (at diagnosis for diagnosed,				
current for PLWH) <13	0	0.0	Æ	
13-19	0	0.0	<5 15	 0.6
20-29	32	38.6	289	12.4
30-39	29	34.9	521	22.3
40-49	13	15.7	455	19.5
50-59	7	8.4	605	25.9
60+	<5		443	19.0
Transmission Category (Unadjusted)	10		110	10.0
Male-to-male sexual contact	34	41.0	888	38.1
Injection drug use	<5		89	3.8
Male-to-male sexual contact and injection drug use	<5		71	3.0
Heterosexual contact ¹	24	28.9	474	20.3
Adult Other ²	0	0.0	24	1.0
Perinatal/other pediatric ³	0	0.0	<5	
Unknown	21	25.3	782	33.5
Transmission Category (Adjusted) ⁴				
Male-to-male sexual contact	49	59.5	1,233	52.9
Injection drug use	<5		156	6.7
Male-to-male sexual contact and injection drug use	<5		91	3.9
Heterosexual contact ¹	28	34.2	800	34.3
Adult Other ²	0	0.0	24	1.0
Perinatal/other pediatric ³	0	0.0	<5	

Table 20. HIV Diagnoses and Persons Living with HIV, District 6 (Augusta), Georgia, 2020

Data for 2020 diagnoses should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing

	HIV diagnoses		PLWH as of 12/31/2020	
	N	%*	N	%*
Total	73	100.0	2,287	100.0
Gender Identity			_,	
Cisgender Male	49	67.1	1,531	66.9
Cisgender Female	19	26.0	729	31.9
Transgender Woman	5	6.8	23	1.0
Transgender Man	0	0.0	<5	
Race/Ethnicity				
Black/Non Hispanic	58	79.5	1,725	75.4
White/Non Hispanic	12	16.4	380	16.6
Hispanic/Latino, Any Race	<5		76	3.3
American Indian/Alaska Native	0	0.0	<5	
Asian/Native Hawaiian/Pacific Islander	0	0.0	5	0.2
Multiple races	0	0.0	83	3.6
Age Group (at diagnosis for diagnosed,				
current for PLWH)				
<13	0	0.0	<5	
13-19	5	6.8	46	2.0
20-29	32	43.8	283	12.4
30-39	21	28.8	435	19.0
40-49	7	9.6	360	15.7
50-59	7	9.6	632	27.6
60+	<5		527	23.0
Transmission Category (Unadjusted)				
Male-to-male sexual contact	37	50.7	898	39.3
Injection drug use	<5		144	6.3
Male-to-male sexual contact and injection drug use	0	0.0	90	3.9
Heterosexual contact ¹	18	24.7	496	21.7
Adult Other ²	0	0.0	74	3.2
Perinatal/other pediatric ³	0	0.0	<5	
Unknown	17	23.3	581	25.4
Transmission Category (Adjusted) ⁴				
Male-to-male sexual contact	47	63.8	1,101	48.2
Injection drug use	<5		199	8.7
Male-to-male sexual contact and injection	<5		103	4.5
drug use Heterosexual contact ¹	22	30.0	789	34.5
Adult Other ²	0	0.0	74	3.2
Perinatal/other pediatric ³	0	0.0	<5	

Table 21. HIV Diagnoses and Persons Living with HIV, District 7 (Columbus), Georgia, 2020

Data for 2020 diagnoses should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing

	HIV dia	agnoses	PLWH as of	12/31/2020
	N	%*	N	%*
Total	87	100.0	1,918	100.0
Gender Identity				
Cisgender Male	58	66.7	1,264	65.9
Cisgender Female	28	32.2	636	33.2
Transgender Woman	<5		12	0.6
Transgender Man	0	0.0	0	0.0
Race/Ethnicity				
Black/Non Hispanic	70	80.5	1,417	73.9
White/Non Hispanic	17	19.5	244	12.7
Hispanic/Latino, Any Race	0	0.0	110	5.7
American Indian/Alaska Native	0	0.0	<5	
Asian/Native Hawaiian/Pacific Islander	0	0.0	<5	
Multiple races	0	0.0	83	4.3
Age Group (at diagnosis for diagnosed,				
current for PLWH) <13	0	0.0	<5	
13-19	5	5.7	13	0.7
20-29	25	28.7	214	11.2
30-39	25	28.7	390	20.3
40-49	16	18.4	411	21.4
50-59	11	12.6	506	26.4
60+	5	5.7	380	19.8
Transmission Category (Unadjusted)				
Male-to-male sexual contact	32	36.8	614	32.0
Injection drug use	<5		105	5.5
Male-to-male sexual contact and injection drug use	0	0.0	44	2.3
Heterosexual contact ¹	30	34.5	522	27.2
Adult Other ²	0	0.0	21	1.1
Perinatal/other pediatric ³	0	0.0	<5	
Unknown	22	25.3	608	31.7
Transmission Category (Adjusted) ⁴				
Male-to-male sexual contact	43	49.2	850	44.3
Injection drug use	5	5.2	147	7.7
Male-to-male sexual contact and injection drug use	<5		60	3.1
Heterosexual contact ¹	39	44.9	773	40.3
Adult Other ²	0	0.0	21	1.1
Perinatal/other pediatric ³	0	0.0	<5	

Table 22. HIV Diagnoses and Persons Living with HIV, District 8-1 (Valdosta), Georgia, 2020

Data for 2020 diagnoses should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing

	HIV di	agnoses	PLWH as of 12/31/2020		
	N	%*	Ν	%*	
Total	47	100.0	1,244	100.0	
Gender Identity			- ,		
Cisgender Male	40	85.1	750	60.3	
Cisgender Female	7	14.9	485	39.0	
Transgender Woman	0	0.0	7	0.6	
Transgender Man	0	0.0	0	0.0	
Race/Ethnicity					
Black/Non Hispanic	37	78.7	861	69.2	
White/Non Hispanic	8	17.0	215	17.3	
Hispanic/Latino, Any Race	<5		98	7.9	
American Indian/Alaska Native	0	0.0	0	0.0	
Asian/Native Hawaiian/Pacific Islander	0	0.0	<5		
Multiple races	0	0.0	57	4.6	
Age Group (at diagnosis for					
diagnosed, current for PLWH)					
<13	0	0.0	<5		
13-19	<5		<5		
20-29	20	42.6	131	10.5	
30-39	4	8.5	229	18.4	
40-49	10	21.3	266	21.4	
50-59	7	14.9	357	28.7	
60+	<5		256	20.6	
Transmission Category (Unadjusted)					
Male-to-male sexual contact	19	40.4	356	28.6	
Injection drug use	0	0.0	53	4.3	
Male-to-male sexual contact and injection	0	0.0	32	2.6	
drug use Heterosexual contact ¹	9	19.1	464	37.3	
Adult Other ²	0	0.0	7	0.6	
Perinatal/other pediatric ³	0	0.0	<5		
Unknown	19	40.4	330	26.5	
Transmission Category (Adjusted) ⁴					
Male-to-male sexual contact	31	65.7	483	38.8	
Injection drug use	<5		78	6.3	
Male-to-male sexual contact and injection	0	0.2	39	3.1	
drug use Heterosexual contact ¹	15	32.6	625	50.3	
Adult Other ²	0	0.0	7	0.6	
Perinatal/other pediatric ³	0	0.0			
	0	0.0	<5		

Table 23. HIV Diagnoses and Persons Living with HIV, District 8-2 (Albany), Georgia, 2020

Data for 2020 diagnoses should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing

	HIV diagnoses		PLWH as of 12/31/2020	
	N	%*	N	%*
Total	77	100.0	1,792	100.0
Gender Identity			, -	
Cisgender Male	44	57.1	1104	61.6
Cisgender Female	32	41.6	673	37.6
Transgender Woman	<5		11	0.6
Transgender Man	0	0.0	<5	
Race/Ethnicity				
Black/Non Hispanic	64	83.1	1433	80.0
White/Non Hispanic	12	15.6	182	10.2
Hispanic/Latino, Any Race	<5		72	4.0
American Indian/Alaska Native	0	0.0	<5	
Asian/Native Hawaiian/Pacific Islander	0	0.0	<5	
Multiple races	0	0.0	90	5.0
Age Group (at diagnosis for diagnosed, current for PLWH)				
<13	0	0.0	<5	
13-19	11	14.3	18	1.0
20-29	27	35.1	225	12.6
30-39	14	18.2	362	20.2
40-49	11	14.3	372	20.8
50-59	10	13.0	449	25.1
60+	<5		362	20.2
Transmission Category (Unadjusted)				
Male-to-male sexual contact	30	39.0	610	34.0
Injection drug use	<5		73	4.1
Male-to-male sexual contact and injection drug use	<5		42	2.3
Heterosexual contact ¹	23	29.9	432	24.1
Adult Other ²	0	0.0	23	1.3
Perinatal/other pediatric ³	0	0.0	<5	
Unknown	21	27.3	609	34.0
Transmission Category (Adjusted) ⁴				
Male-to-male sexual contact	36	47.1	807	45.0
Injection drug use	5	6.1	123	6.9
Male-to-male sexual contact and injection drug use	<5		53	3.0
Heterosexual contact ¹	35	45.3	771	43.0
Adult Other ²	0	0.0	23	1.3
Perinatal/other pediatric ³	0	0.0	<5	

Table 24. HIV Diagnoses and Persons Living with HIV, District 9-1 (Savannah), Georgia, 2020

Data for 2020 diagnoses should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing

	HIV diagnoses		PLWH as of 12/31/2020	
	N	%*	N	%*
Total	101	100.0	2,823	100.0
Gender Identity				
Cisgender Male	76	75.2	1,894	67.1
Cisgender Female	23	22.8	896	31.7
Transgender Woman	<5		22	0.8
Transgender Man	0	0.0	<5	
Race/Ethnicity				
Black/Non Hispanic	69	68.3	1,865	66.1
White/Non Hispanic	21	20.8	579	20.5
Hispanic/Latino, Any Race	7	6.9	192	6.8
American Indian/Alaska Native	0	0.0	<5	
Asian/Native Hawaiian/Pacific Islander	<5		11	0.4
Multiple races	0	0.0	139	4.9
Age Group (at diagnosis for diagnosed, current for PLWH)				
<13	0	0.0	8	0.3
13-19	6	5.9	16	0.6
20-29	35	34.7	318	11.3
30-39	28	27.7	615	21.8
40-49	10	9.9	483	17.1
50-59	16	15.8	772	27.3
60+	6	5.9	610	21.6
Transmission Category (Unadjusted)				
Male-to-male sexual contact	42	41.6	1,057	37.4
Injection drug use	<5		153	5.4
Male-to-male sexual contact and injection drug use	<5		65	2.3
Heterosexual contact ¹	16	15.8	551	19.5
Adult Other ²	0	0.0	34	1.2
Perinatal/other pediatric ³	0	0.0	7	0.2
Unknown	39	38.6	956	33.9
Transmission Category (Adjusted) ⁴				
Male-to-male sexual contact	60	58.9	1,427	50.6
Injection drug use	6	6.1	229	8.1
Male-to-male sexual contact and injection drug use	<5		90	3.2
Heterosexual contact ¹	31	30.4	998	35.4
Adult Other ²	0	0.0	34	1.2
Perinatal/other pediatric ³	0	0.0	7	0.2

Table 25. HIV Diagnoses and Persons Living with HIV, District 9-2 (Waycross), Georgia, 2020

Data for 2020 diagnoses should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing

	HIV diagnoses		PLWH as of	12/31/2020
	N	%*	N	%*
Total	47	100.0	1,266	100.0
Gender Identity				
Cisgender Male	38	80.9	834	65.9
Cisgender Female	8	17.0	424	33.5
Transgender Woman	<5		7	0.6
Transgender Man	0	0.0	0	0.0
Race/Ethnicity				
Black/Non Hispanic	26	55.3	772	61.0
White/Non Hispanic	13	27.7	267	21.1
Hispanic/Latino, Any Race	7	14.9	115	9.1
American Indian/Alaska Native	0	0.0	0	0.0
Asian/Native Hawaiian/Pacific Islander	0	0.0	<5	
Multiple races	<5		84	6.6
Age Group (at diagnosis for diagnosed,				
current for PLWH)				
	0	0.0	0	0.0
13-19	<5		<5	
20-29	18	38.3	118	9.3
30-39	15	31.9	268	21.2
40-49	5	10.6	260	20.5
50-59	5	10.6	374	29.5
60+	<5		242	19.1
Transmission Category (Unadjusted)				
Male-to-male sexual contact	18	38.3	410	32.4
Injection drug use	<5		65	5.1
Male-to-male sexual contact and injection drug use	<5		39	3.1
Heterosexual contact ¹	10	21.3	309	24.4
Adult Other ²	0	0.0	12	0.9
Perinatal/other pediatric ³	0	0.0	0	0.0
Unknown	16	34.0	431	34.0
Transmission Category (Adjusted) ³				
Male-to-male sexual contact	28	60.2	575	45.5
Injection drug use	<5		105	8.3
Male-to-male sexual contact and injection drug use	<5		50	3.9
Heterosexual contact ¹	15	30.9	498	39.4
Adult Other ²	0	0.0	12	0.9
Perinatal/other pediatric ³	0	0.0	0	0.0

Table 26. HIV Diagnoses and Persons Living with HIV, District 10 (Athens), Georgia, 2020

Data for 2020 diagnoses should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing

	HIV diagnoses		PLWH as of	12/31/2020
	N	%*	N	%*
Total	42	100.0	1,101	100.0
Gender Identity				
Cisgender Male	30	71.4	742	67.4
Cisgender Female	10	23.8	339	30.8
Transgender Woman	<5		17	1.5
Transgender Man	<5		<5	
Race/Ethnicity				
Black/Non Hispanic	23	54.8	610	55.4
White/Non Hispanic	10	23.8	326	29.6
Hispanic/Latino, Any Race	5	11.9	91	8.3
American Indian/Alaska Native	0	0.0	0	0.0
Asian/Native Hawaiian/Pacific Islander	<5		7	0.6
Multiple races	<5		56	5.1
Age Group (at diagnosis for diagnosed,				
current for PLWH)	0	0.0	-	
<13	0	0.0	<5	
13-19	<5		8	0.7
20-29	17	40.5	126	11.4
30-39	10	23.8	258	23.4
40-49 50-59	<5	9.5 14.3	227	20.6 23.8
60+	6 <5	9.5	262 217	23.8 19.7
	<0	9.5	217	19.7
Transmission Category (Unadjusted) Male-to-male sexual contact	23	54.8	448	40.7
	23 <5		62	5.6
Injection drug use				
Male-to-male sexual contact and injection drug use Heterosexual contact ¹	0	0.0	34	3.1 20.4
	10	23.8	225	
Adult Other ²	0	0.0	13	1.2
Perinatal/other pediatric ³	0	0.0	<5	
Unknown	7	16.7	316	28.7
Transmission Category (Adjusted) ⁴ Male-to-male sexual contact	05	50.0	E0 4	FO O
	25	59.0	584	53.0
Injection drug use	<5		86	7.8
Male-to-male sexual contact and injection drug use	0	0.0	42	3.8
Heterosexual contact ¹	13	31.0	362	32.9
Adult Other ²	0	0.0	13	1.2
Perinatal/other pediatric ³	0	0.0	<5	

HIV Diagnoses and Persons Living with HIV, Atlanta MSA

Table 27. HIV Diagnoses and Persons Living with HIV, Atlanta Metropolitan Statistical Area¹, Georgia, 2020

	HIV dia	HIV diagnoses		12/31/2020
	N	%*	N	%*
Total	1,379	100.0	42,257	100.0
Gender Identity				
Cisgender Male	1,094	79.3	33,226	78.6
Cisgender Female	239	17.3	8,432	20.0
Transgender Woman	43	3.1	507	1.2
Transgender Man	<5		24	0.1
Race/Ethnicity				
Black/Non Hispanic	1,008	73.1	29,182	69.0
White/Non Hispanic	183	13.3	6,945	16.4
Hispanic/Latino, Any Race	142	10.3	3,342	7.9
American Indian/Alaska Native	<5		20	0.0
Asian/Native Hawaiian/Pacific Islander	15	1.1	273	0.6
Multiple races	16	1.2	1,956	4.6
Age Group (at diagnosis for diagnosed,				
current for PLWH)	<u> </u>		50	
<13	<5		50	0.1
13-19	62	4.5	175	0.4
20-29	576	41.8	4,740	11.2
30-39	392	28.4	10,439	24.7
40-49	173	12.5	9,089	21.5
50-59	128	9.3	10,958	25.9
60+	47	3.4	6,806	16.1
Transmission Category (Unadjusted)				
Male-to-male sexual contact	855	62.0	24,011	56.8
Injection drug use	15	1.1	1,375	3.3
Male-to-male sexual contact and injection drug use	19	1.4	1,336	3.2
Heterosexual contact ²	213	15.4	6,127	14.5
Adult Other ³	0	0.0	347	0.8
Perinatal/other pediatric4	0	0.0	44	0.1
Unknown	277	20.1	9,026	21.4
Transmission Category (Adjusted) ⁵				
Male-to-male sexual contact	988	71.7	28,396	67.2
Injection drug use	31	2.3	1,988	4.7
Male-to-male sexual contact and injection	24	1.7	1,631	3.9
drug use Heterosexual contact ²	322	23.3	9,307	22.0
Adult Other ³	0	0.0	347	0.8
Perinatal/other pediatric ⁴	0	0.0	44	0.1
	0	5.0		0.1

*Percents may not add up to 100 due to rounding 1.Barrow, Bartow, Butts, Carroll, Cherokee, Clayton, Cobb, Coweta, Dawson, DeKalb, Douglas, Fayette, Forsyth, Fulton, Gwinnett, Haralson, Heard, Henry, Jasper, Lamar, Meriwether, Morgan, Newton, Paulding, Pickens, Pike, Rockdale, Spalding, Walton 2.Heterosexual contact: Defined as sexual contact with someone of the opposite sex with known risk such as injection drug use, bisexual male (applies to females only), person with hemophilia/coagulation disorder, transfusion recipient with HIV documentation, and or person with AIDS or documented HIV. 3. Includes perinatal exposure age_13, hemophilia, blood transfusion.4. Perinatal/other pediatric: cases <13 years born to HIV-infected mother, and cases <13 with missing risk. 5. Adjusted for missing risk using multiple imputation methods. Adjusted subtotals may be different from unadjusted subtotals due to rounding

2020 Georgia HIV Surveillance Summary

Late Diagnoses by Public Health District and Atlanta MSA

Table 28. Late diagnoses by Public Health District and for Atlanta Metropolitan Statistical Area, Georgia, 2020

Data for 2020 diagnoses should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing

	HIV Diagnoses		Diagnoses within 12 months
	N	N	row %
District			
1-1 Northwest (Rome)	53	17	32.1
1-2 North Georgia (Dalton)	23	5	21.7
2 North (Gainesville)	48	12	25.0
3-1 Cobb-Douglas	160	42	26.3
3-2 Fulton	481	92	19.1
3-3 Clayton (Jonesboro)	113	21	18.6
3-4 East Metro (Lawrenceville)	185	43	23.2
3-5 DeKalb	278	60	21.6
4 LaGrange	96	16	16.7
5-1 South Central (Dublin)	16	4	25.0
5-2 North Central (Macon)	83	19	22.9
6 East Central (Augusta)	73	18	24.7
7 West Central (Columbus)	87	26	29.9
8-1 South (Valdosta)	47	14	29.8
8-2 Southwest (Albany)	77	22	28.6
9-1 Coastal (Savannah)	101	28	27.7
9-2 Southeast (Waycross)	47	10	21.3
10 Northeast (Athens)	42	10	23.8
Atlanta MSA ¹	1,379	298	21.6

1. Barrow, Bartow, Butts, Carroll, Cherokee, Clayton, Cobb, Coweta, Dawson, DeKalb, Douglas, Fayette, Forsyth, Fulton, Gwinnett, Haralson, Heard, Henry, Jasper, Lamar, Meriwether, Morgan, Newton, Paulding, Pickens, Pike, Rockdale, Spalding, Walton

Public Health District and County Rates

Table 29. HIV diagnoses and persons living with HIV (PLWH): Public Health District and County number and rates per100,000 population, Georgia, 2020

Data for 2020 diagnoses should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing

	HIV Diagnoses (all stages)		PLWH as of 12/31/2020		
	N ¹	Rate/100,000 ^{2,3}	N ¹	Rate/100,000 ^{2,3}	
1-1 Northwest (Rome)	53	7.7	1,239	178.9	
Bartow County	8	7.3	233	212.9	
Catoosa County	<5		72	105.9	
Chattooga County	0	0.0	53	213.3	
Dade County	<5		15	93.4	
Floyd County	13	13.2	245	248.5	
Gordon County	<5		74	125.9	
Haralson County	<5		35	115.2	
Paulding County	21	12.1	370	213.4	
Polk County	<5		66	154.1	
Walker County	<5		76	108.4	
1-2 North Georgia (Dalton)	23	4.6	722	144.2	
Cherokee County	12	4.5	403	151.9	
Fannin County	<5		36	135.7	
Gilmer County	<5		60	187.6	
Murray County	<5		36	89.9	
Pickens County	<5		40	120.7	
Whitfield County	<5		147	141.6	
2 North (Gainesville)	48	6.4	963	129.1	
Banks County	0	0.0	13	67.2	
Dawson County	<5		31	114.3	
Forsyth County	14	5.6	228	90.9	
Franklin County	<5		45	191.5	
Habersham County	5	10.9	75	162.9	
Hall County	16	7.7	350	169.4	
Hart County	<5		48	181.8	
Lumpkin County	0	0.0	37	108.2	
Rabun County	0	0.0	20	115.8	
Stephens County	<5		49	187.7	
Towns County	<5		9	73.5	
Union County	<5		33	130.1	
White County	<5		25	80.4	
3-1 Cobb/Douglas	160	17.6	4,311	473.3	
Cobb County	137	18.0	3,619	474.3	
Douglas County	23	15.5	692	467.6	
3-2 Fulton	481	44.6	16,377	1520.0	
Fulton County	481	44.6	16,377	1520.0	
3-3 Clayton	113	38.6	3,056	1044.3	
Clayton County 3-4 East Metro	113	38.6	3,056	1044.3	
(Lawrenceville)	185	16.1	4,532	395.2	
Gwinnett County	150	15.9	3,672	389.5	
Newton County	22	19.4	417	368.1	

Rockdale County	13	14.3	443	487.1
3-5 DeKalb	278	36.5	9,974	1308.9
DeKalb County	278	36.5	9,974	1308.9
4 LaGrange				
	96	10.8	2,529	284.6
Butts County	10	39.3	116	456.2
Carroll County	8	6.6	254	208.8
Coweta County	13	8.6	285	188.9
Fayette County	8	6.9	229	197.7
Heard County	0	0.0	14	116.9
Henry County	39	16.3	1,005	420.3
Lamar County	<5		47	244.0
Meriwether County	<5		75	354.4
Pike County	0	0.0	13	68.0
Spalding County	6	8.9	227	336.7
Troup County	7	10.0	196	279.1
Upson County	-5	3.8	68	256.3
5-1 South Central (Dublin)	16	10.7	608	406.3
Bleckley County	<5		48	370.5
Dodge County	<5		80	391.2
Johnson County	<5		32	331.0
Laurens County	8	16.8	197	414.6
Montgomery County	0	0.0	15	166.4
Pulaski County	0	0.0	25	223.4
Telfair County	0	0.0	88	557.6
Treutlen County	<5		23	337.1
Wheeler County	0	0.0	31	399.9
Wilcox County	<5		69	811.6
5-2 North Central (Macon)	83	15.4	2,332	433.8
Baldwin County	<5		164	363.6
Bibb County	42	27.5	1,249	817.7
Crawford County	<5		23	188.0
			45	
Hancock County	<5			529.8
Houston County	21	13.1	456	284.8
Jasper County	<5		23	158.8
Jones County	<5		48	166.7
Monroe County	<5		57	203.3
Peach County	5	17.9	127	454.4
Putnam County	<5		36	159.9
Twiggs County	0	0.0	23	283.8
Washington County	<5		60	297.8
Wilkinson County	0	0.0	21	238.3
6 East Central (Augusta)	73	14.8	2,287	462.7
Burke County	5	22.1	101	446.0
Columbia County	8	5.0	236	147.2
-				
Emanuel County	0	0.0	61	271.0
Glascock County	0	0.0	7	234.6
Jefferson County	5	32.8	57	373.4
Jenkins County	0	0.0	34	388.7
Lincoln County	<5		18	224.1
McDuffie County	<5		63	297.7
Richmond County	50	24.7	1,611	797.2
Screven County	<5		46	328.3
Taliaferro County	0	0.0	9	576.2
Warren County	<5		20	382.3
Wilkes County	0	0.0	24	247.6
7 West Central (Columbus)	87	23.6	1,918	519.4
Chattahoochee County	0	0.0	13	123.2

2020 Georgia HIV Surveillance Summary

	0	0.0	10	450.0
Clay County	0	0.0	13	453.6
Crisp County	7	31.8	141	639.9
Dooly County	<5		65	493.4
Harris County	<5		44	122.0
Macon County	<5		72	566.4
Marion County	0	0.0	14	164.4
Muscogee County	68	34.6	1,176	598.6
Quitman County	0	0.0	5	220.2
Randolph County	<5		42	628.6
Schley County	0	0.0	6	115.5
Stewart County ⁴	0	0.0	123	1838.8
Sumter County	<5		142	484.9
Talbot County	0	0.0	27	439.5
Taylor County	0	0.0	32	396.3
Webster County	0	0.0	3	115.6
8-1 South (Valdosta)	47	18.1	1,244	479.1
Ben Hill County	<5		58	349.1
Berrien County	0	0.0	39	200.9
•	<5		63	410.2
Brooks County				
Cook County	5	28.9	76	439.5
Echols County	<5		15	374.8
Irwin County	<5		86	916.2
Lanier County	<5		25	232.8
Lowndes County	27	22.8	663	560.6
Tift County	8	19.6	171	420.0
Turner County	<5		48	609.0
8-2 Southwest (Albany)	77	22.6	1,792	526.1
Baker County	0	0.0	7	235.6
Calhoun County	0	0.0	34	545.7
Colquitt County	11	24.2	210	461.1
Decatur County	6	22.7	136	514.0
Dougherty County	38	43.9	791	914.7
Early County	0	0.0	26	259.0
Grady County	<5		69	281.7
Lee County	<5		73	241.5
Miller County	0	0.0	20	355.7
Mitchell County	5	23.1	108	500.0
Seminole County	<5		25	310.2
Terrell County	0	0.0	44	516.3
Thomas County	7	15.8	172	387.6
Worth County	<5		77	385.5
9-1 Coastal (Savannah)	101	15.9	2,823	444.9
Bryan County	<5		56	137.4
Camden County	0	0.0	99	178.7
	63			649.5
Chatham County	6	21.8	1,880	
Effingham County		9.1	93	141.4
Glynn County	18	21.0	358	418.4
Liberty County	12	19.0	255	404.7
Long County	0	0.0	24	119.0
McIntosh County	0	0.0	58	403.1
9-2 Southeast (Waycross)	47	12.5	1,266	337.1
Appling County	<5		39	212.8
Atkinson County	<5		21	250.2
Bacon County	<5		43	389.6
Brantley County	0	0.0	21	109.4
Bulloch County	14	17.3	278	343.9
Candler County	0	0.0	34	309.5

Charlton County	<5		74	551.0
Clinch County	0	0.0	27	410.2
Coffee County	6	13.9	124	286.9
Evans County	<5		47	441.8
Jeff Davis County	0	0.0	31	203.8
Pierce County	<5		30	153.7
Tattnall County	<5		102	402.1
Toombs County	<5		97	359.6
Ware County	6	16.7	183	510.8
Wayne County	<5		115	383.0
10 Northeast (Athens)	42	7.9	1,101	207.3
Barrow County	6	7.0	141	164.7
Clarke County	23	18.0	459	359.2
Elbert County	<5		40	206.9
Greene County	<5		30	159.3
Jackson County	0	0.0	88	115.5
Madison County	<5		37	121.5
Morgan County	<5		36	183.3
Oconee County	<5		29	70.5
Oglethorpe County	<5		30	195.0
Walton County	<5		211	217.8

1. Values of 1-4 are censored 2. Rates are not calculated when numerator is <12. 3. Persons residing in correctional facilities are included in this report and may inflate rates in certain geographic regions where there are large numbers of HIV-positive inmates. 4. Most cases associated with a federal immigration detention facility located in this county.

Distribution of General Population by Race/Ethnicity

Table 30. Distribution of the general population by race/ethnicity, Georgia 2020

Race/Ethnicity	Number (%)
White, Non-Hispanic	5,522,339
Black, Non-Hispanic	3,406,103
Hispanic/Latino, Any Race	1,067,941
Asian, Non-Hispanic	471,825
American Indian /Alaskan Native, Non-Hispanic	24,535
Native Hawaiian/Pacific Islander, Non-Hispanic	7,564
Total	10,710,017

Source: Georgia Online Analytical Statistical Information System (<u>https://oasis.state.ga.us/oasis/webguery/qryPopulation.aspx</u>)

HIV/AIDS RESOURCES:



Georgia Department of Public Health http://dph.georgia.gov/what-hiv-and-aids



Centers for Disease Control and Prevention http://www.cdc.gov/hiv/



AIDSVu http://aidsvu.org/

Reporting

- All health care providers diagnosing and/or providing care to a patient with HIV are required by Georgia law (O.C.G.A. §31-12-1) to report HIV infection using the HIV/AIDS Case Report Form.
- Case report forms should be completed within seven (7) days of diagnosing a patient with HIV and/or AIDS or within seven (7) days of assuming care of an HIV positive patient who is new to the provider, regardless of whether the patient has previously received care elsewhere.
- Adult and Pediatric case report forms are available at
 https://dph.georgia.gov/hivaids-case-reporting
- For more questions on HIV case reporting in Georgia please contact the HIV Surveillance Coordinator at 1-800-827-9769